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Abstract 
 
 
 
Microglial activation was previously associated with neurodegenerative diseases such as 
Parkinson’s disease (PD) or Alzheimer’s disease (AD). The prototype of primary microglia 
neurodegenerative disorder is represented by the Nasu-Hakola disease (NHD), which is caused 
by loss of function mutations in the microglial triggering receptor expressed in myeloid cells 2 
(TREM2) or its associated adaptor molecule DNAX-activating protein of molecular mass 12 kDa 
(DAP12). Recently, mutations in TREM2 were associated with late onset AD (LOAD). The 
mechanisms of TREM2/DAP12-mediated neurodegeneration are still not fully understood. 
Within this thesis, in vitro and/or in vivo models of NHD, PD and LOAD were investigated with 
an emphasis on the mechanisms of microglia-mediated neurodegeneration.  
As model for NHD, TREM2 knock-out (KO) animals were found to develop an activated-like 
microglial phenotype when compared with appropriate wild type (WT) controls. However, only 
the old TREM2 KO animals present altered microglial-related gene expressions. Systemic 
lipopolysaccharide (LPS) stimulation of mice accentuated the differences in TREM2 KO 
microglial phenotype, but without inducing significant differences between microglia-related 
proinflammatory transcripts in TREM2 KO compared with control mice. LPS challenges were 
previously associated with dopaminergic loss, a neuropathological trait of PD. To investigate the 
mechanism of LPS-triggered dopaminergic degeneration, WT mice were challenged with LPS 
and transcriptome analysis of whole brains was performed. The analysis revealed enrichement 
in microglial phagosiome and complement-related genes. To prove the complement 
involvement in neuronal loss, C3 KO animals were challenged with LPS. Dopaminergic neuronal 
loss was found to be ameliorated in C3 KO mice. LOAD investigation using genome wide 
association studies revealed specific enrichment of the immune-related module, with DAP12 
acting as causal regulator. Modified microglia cell lines overexpressing functional or non-
functional DAP12 were generated and were able to recapitulate expression patterns specific to 
LOAD brains. Furthermore, microglial cells were able to take up amyloid and release neurotoxic 
superoxide only when expressing functional DAP12.  
The present thesis proposes microglial-related mechanisms in which different immune-related 
pathways are converging, contributing to the neurodegenerative processes.  
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1. Introduction 
 
 
 
 
Evolutionary pressure drove living organisms into gradually developing more sophisticated 
defense mechanisms against potential dangerous foreign entities, culminating with the 
formation of complex immune system. In vertebrates, the immune system encompasses a 
highly intricate and dynamic network of cells, tissues and organs capable to recognize and 
appropriately respond to a broad variety of dangerous or non-self structures. However, in 
certain conditions, these mechanisms can turn against own structures, as in the case of 
neurodegenerative diseases. 
 
1.1 Microglia - the Brain’s Immune Cells 
 
The resident innate immune cells exclusive to central nervous system (CNS) are represented by 
microglia. Even though many microglial properties were known from anatomy and pathology 
studies of the late 19th century, the concept of microglial cell was first introduced by Pió del Rió-
Hortega in 1932 (Barron, 1995; Kettenmann and Hanisch, 2011). After this period, the study of 
microglia entered a decline until the 1960s when many debates and questions related with the 
brain immunity reemerged. 
Most of del Rió-Hortega’s observations on microglial cells remain valid until today. Indeed 
microglial cells have a mesodermal origin, entering the future brain during early development, 
when they present amoeboid morphology. After reaching their final anatomical destination, 
they display a branched cellular phenotype, presenting little variation and occupying defined 
non-overlapping territory. Upon a pathological event, microglia can ‘transform’, becoming 
again amoeboid. However, some of the intimate mechanisms of microglial physiology remained 
elusive to the scientific community. 
Additional to the microglial population, the CNS presents macrophage populations associated 
with blood vessels (the perivascular macrophages, sometimes named also ‘perivascular 
microglia’), circumventricular organs, choroid plexus and meninges. However, these cells can be 
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distinguished from microglial cells based on their morphological differences and localization 
(Ransohoff and Perry, 2009). 
 
1.1.1 Origin and Localization of Microglial Cells 
 
Even though the origin of microglia has been long debated, the present commonly accepted 
hypothesis supports a first wave of migration starting from the yolk sack and reaching the 
embryo between embryonic day (E)7-7.5 and E8 in mice, then populating the future CNS 
around E10 (Alliot et al., 1999; Ginhoux et al., 2010; Kierdorf et al., 2013). The second wave of 
sporadic microglial migration occurs at postnatal (P) stages, when circulating bone marrow 
derived monocytes enter the brain, in mice between P0-P15 (Chan et al., 2007; Soulet and 
Rivest, 2008). However, the exact identity of these monocytes is still unclear. After this stage, 
the blood brain barrier (BBB) becomes highly restrictive and the exchange of cells between 
blood and brain is mostly stopped (Galea et al., 2007). 
In the adult organism, microglial cells are found throughout the whole CNS, encompassing 5-
20% of the adult brain cells, with higher densities in the grey matter (Lawson et al., 1990). More 
precisely, an increased number of microglia can be found in the hippocampus, olfactory 
telencephalon and basal ganglia, an average microglial cells density can be found in the cerebral 
cortex, thalamus and hypothalamus, and a lower density in fiber tracts, cerebellum and most of 
the brainstem (Lawson et al., 1990). 
The microglial turnover was assessed initially in irradiation chimera studies (in which 
transplanted bone marrow replaces the constitutive irradiated monocytic cell population with 
newly derived monocyte population) or experimental autoimmune encephalomyelitis mice 
(EAE, the model for human multiple sclerosis, MS, which affects CNS and is characterized by an 
increase of immune cells at the lesion site). These studies led to the belief that brain immune 
cells are replenished with populations coming from the periphery (Hickey and Kimura, 1988; 
Lassmann et al., 1993). However, the BBB integrity was altered in all these studies, a 
phenomenon which does not occur in the physiological normal brain. Further studies showed 
that indeed green fluorescence protein (GFP) labeled monocytes can enter the brain, but only 
after a ‘preconditioning’ step (as in the case of irradiation (Mildner et al., 2007). Another paper 
reported in EAE mice different behavior and physiology between resident microglia and 
infiltrating monocytes (Ajami et al., 2011). Moreover, based on specific markers expression and 
activation responses, different microglial subpopulation were recently described, suggesting 
that there could be different and more specialized functional subtypes of microglia inside the 
brain (Chen et al., 2010; Scheffel et al., 2012). 
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1.1.2 Microglial Functions and Morphology 
 
Due to the presence of the BBB that blocks the transit of other specialized immune cells inside 
CNS, the brain is considered to be an immunoprivileged organ (Galea et al., 2007). Microglial 
ability to integrate the signals received from the surrounding parenchyma is accomplished via 
different intracellular signaling cascades that conclude in generating a prompt and accurate 
response. Most importantly, this process is achieved in the absence of mediation from other 
more specialized immune cell types, as in the case of peripheral immunity. 
Microglial cells were described as being both beneficial and detrimental, with a thin line 
between the two states. This can be explained due to the microglial cells ability to integrate a 
huge variety of signals or even modulate responses elicited via a single type of stimulation. For 
example, microglial cells are able to detect glutamate neurotransmitter release due to 
glutamate receptors present on the cell surface, leading to either neuroprotective or neurotoxic 
outcome (Kaushal and Schlichter, 2008; Taylor et al., 2003).  
The morphological differences seen in microglia were for a long time attributed to a simple 
linear model of microglial progression from the beneficial ‘resting’ state to the amoeboid 
activated state. However, many studies were able to show that microglia present various 
intermediary and interchangeable morphological and functional states, proving the inaccuracy 
of the linear model (Perry et al., 2007; Ransohoff and Perry, 2009; Sierra et al., 2013; Wake et 
al., 2013). 
 
1.1.2.1 The Beneficial Microglia 
 
In the physiological healthy brain, the microglia can be found in a ramified phenotype, 
historically labeled as ‘resting’ or ‘quiescent’ (Kettenmann and Hanisch, 2011; Perry et al., 2010; 
Ransohoff and Engelhardt, 2012). However, microglial cells in this state are not dormant and 
their processes are not immobile, but continuously scanning the brain parenchyma, as 
demonstrated by two-photon microscopy studies (Davalos et al., 2005; Nimmerjahn et al., 
2005). Interestingly, the area covered by microglia and its processes is highly individualized, 
with no overlapping territories (Jinno et al., 2007).   
Microglial role was evidentiated in mice since CNS development, when deficits of the 
complement components C1q and C3 led to dysfunctions in synaptic pruning of the optic nerve 
(Schafer et al., 2012; Stevens et al., 2007). The intimate interaction of microglia with synapses 
was demonstrated also in other studies (Tremblay et al., 2010; Wake et al., 2009). Microglial 
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implication in synaptic regulation was also described in a study investigating delayed postnatal 
maturation of hippocampal circuits after impairment of microglial signaling via the fractalkine 
receptor (Paolicelli et al., 2011). The development of cerebellum is characterized by a reduction 
in Purkinje cells via apoptosis in which microglial phagocytosis contributs to the elimination of 
the resulted apoptotic material (Marín-Teva et al., 2004). Interestingly, microglial molecules 
that are traditionally linked to proinflammatory functions seem to be involved also in normal 
brain development, as demonstrated in tumor necrosis factor α (Tnfα) deficient mice that 
present visual cortex functional impairments (Kaneko et al., 2008). 
Microglial involvement in neurogenesis and neuronal survival was also documented in several 
studies. Neurogenesis in hippocampal slice cultures was observed only in the presence of 
microglial cells (Sierra et al., 2010). However another study showed in vivo that neurogenesis 
can be increased by inihibition of microglial proinflammatory activation (Monje et al., 2003). 
Microglia can release molecules with beneficial functions for the neuronal parenchyma. For 
example brain-derived neurotrophic factor (BDNF) was suggested to be produced by microglia 
to stimulate wound axonal sprouting (Batchelor, 2002) or to modulate the neuronal activity 
(Coull et al., 2005). Glycine released by microglia plays a role in neuron-microglia 
communications by activating the N-methyl-D-aspartate (NMDA) receptors of neurons (Hayashi 
et al., 2006). Pascual and colleagues observed an indirect action of microglia on neurons via 
astrocytic mediation, in which microglial adenosine triphosphate (ATP) is released, leading to 
subsequent glutamate discharge by astrocytes and thus contributing to neuronal activity 
(Pascual et al., 2012). In animals models of traumatic injury and stroke, microglia release Il10 or 
Tgfβ, which also present neuroprotective effects (Hanisch and Kettenmann, 2007; Streit, 2002).  
It is considered that microglia are kept in an immune-suppressed state due to the presence of 
the so called ‘off signals’ mediated by a variety of ligand-receptor interaction. These off signals 
are generated for example by members of the immunoglobulin superfamily like neuronal 
cluster of differentiation 200 (CD200) recognized by the microglial CD200 receptor (CD200R), 
CD47-CD172a (signal regulatory protein α, SIRPα) or CD22-CD45 (Biber et al., 2007; Galea et al., 
2007; Perry et al., 2010; Ransohoff and Cardona, 2010). Other off signals are represented by 
neuronal fractalkine (CX3C Chemokine Ligand 1, CX3CL1) recognized by the microglial 
fractalkine receptor (CX3CR1), neuronal intracellular adhesion molecule 5 (ICAM5) recognized 
by microglial receptor lymphocyte function associated antigen 1 (LFA1 or αLβ2-integrin, formed 
of CD11a and CD18), interleukin 10 (IL10) and its microglial receptor IL10R, transforming growth 
factor β (TGFβ) and its microglial receptor TGFβR, and also neurotransmitters (Biber et al., 
2007; Galea et al., 2007; Perry et al., 2010; Ransohoff and Cardona, 2010). Importantly for 
further discussions, many of the immune-suppressing receptors present on microglia signal via 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and thus changes in the availability of 
these signals lead to microglial activation. 
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Another important function of microglia is phagocytosis. The ability of microglial cells to 
phagocytosis or even to phagoptose (in case of whole cell ingestion) is generated by the 
recognition of the so called ‘eat-me’ signals on the structures to be internalized (Brown and 
Neher, 2012; Sierra et al., 2013). Microglia can recognize the ‘eat-me’ signals due to expression 
of specific receptors and respond accordingly to the stimuli, by either proinflammatory or 
antiinflammatory mechanisms (Ravichandran and Lorenz, 2007). Phagocytosis in the absence of 
inflammation is a key aspect of CNS immunity (Neumann et al., 2008). In neurodegenerative 
diseases, microglia are involved in the removal of potentially dangerous material, such as in 
taking up amyloid β (Aβ) in the case of Alzheimer’s disease, AD (Melchior et al., 2010) or myelin 
debris in MS and EAE models (Bauer et al., 1994). 
 
1.1.2.2 The Harmful Microglia 
 
Alterations of the normal functions of the organism and/or its lower levels of organization can 
affect also the normal function of CNS. Generally, the detrimental functions of microglia inside 
CNS were studied more extensively and were more evident compared with the functions of the 
immunosupressed microglia.  
Subsequent to injury or infection, a systemic response is triggered inside the organism, that 
leads to metabolic and sickness-behavior changes (Perry et al., 2007). The immune 
communication between the periphery and CNS was described as being mediated via three 
different routes: a direct path through the vagal nerve, another through cytokines and other 
inflammatory molecules carried to sites lacking BBB protection (and thus reaching directly the 
brain parenchyma), and an indirect path through mediation of the perivascular macrophages 
that respond to changes in blood composition (Perry et al., 2007). After recognition and 
integration of these specific stimuli (as well as in the case of direct brain damage), microglia can 
become activated, changing their morphology progressively from the ramified state to an 
amoeboidal state (Kreutzberg, 1996). Beside these extrinsic stimuli, microglial phenotype and 
function are altered by intrinsic stimuli, as for example by Runt related transcription factor 1 
(Runx1) or interferon regulatory factor 8 (Irf8), which regulate microglial morphological changes 
(Minten et al., 2012; Zusso et al., 2012).  
Following acute brain injury, microglial cells are able to quickly extend their processes to the 
lesion site (Davalos et al., 2005) and even to move the entire cellular body towards the lesion 
(Meyer-Luehmann et al., 2008). Moreover, there are evidences pointing out that migration is 
required for the initiation of other functions, as it was demonstrated in mice lacking the CXC 
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chemokine receptor 3 (CXCR3), in which microglia do not migrate and as a consequence cannot 
remove dendrites after brain injury (Rappert et al., 2004). 
 
Figure 1.1 – Pattern recognition receptors (PRRs) on the surface of microglia. Microglial cells can identify 
and internalize extracellular molecules (see box) by recognizing molecular via PRRs or PRR complexes. 
Subsequently, a specific response is build, consisting in phagocytosis and lysosome-mediated degradation 
of the internalized structures, release of superoxide (O2·
-
) for killing microbes, or secretion of 
proinflammatory molecules for intercellular communication (acronyms detailed in the ‘abbreviations’ 
section; modified from(Block et al., 2007).  
The damage-associated molecular pattern molecules (DAMPs) found at the site of injury or 
molecules released by damaged or degenerating cells are recognized by specialized receptors 
present on microglial surface (Fig. 1.1), like scavenger receptors (Bamberger et al., 2003), toll-
like receptors (TLRs; Olson and Miller, 2004) or purinergic receptors (Koizumi et al., 2007). By 
receptor engagement, microglial cells are able to recognize pathogen-associated molecular 
patterns (PAMPs) like lipopolysaccharides (LPS) found in the gram negative bacterial wall, 
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double stranded ribonucleic acids (dsRNA) or other microorganism and viruses related 
molecules (Kettenmann and Hanisch, 2011; Neumann et al., 2008). Interestingly, in certain 
pathological conditions, microglia can even be activated by otherwise beneficial self molecules, 
which are normally not found inside the brain parenchyma, like the serum component 
fibrinogen (Adams et al., 2007).  
Another response to microglial activation is the release of a highly diversified variety of soluble 
factors, like proinflammatory cytokines including interleukins (IL1β, IL2, IL6), TGFβ1, 
macrophage colony-stimulating factor (MCSF), granulocyte-macrophage colony stimulating 
factor (GMCSF) or TNFα (Cunningham et al., 2005; Kreutzberg, 1996).  
Based on the receptors expressed or the response to specific stimuli, there was a tendency to 
classify microglia by using a system developed in macrophages (Mantovani et al., 2002). Within 
this system, cells are divided within a classical M1 phenotype (stimulated by LPS plus 
interferon-γ, IFNγ) or the alternatively activated states M2a (stimulated by IL4/IL13), M2b (IL1) 
or M2c (TGFβ, Il10). However, microglia are significantly different than peripheral macrophages 
in regard to their activation pattern (Ransohoff and Perry, 2009) and thus this classification 
terminology is inadequate when referring to microglial cells. 
Additionally, microglial response to dangerous signals implies activation of nitric oxide synthase 
(NOS; Saha and Pahan, 2006) or nicotinamide adenine dinucleotide phosphate oxidase (NADPH 
oxidase; Block, 2008), which generates either nitric oxide (NO) or superoxide (O2·
-). Both NO 
and O2·
- are toxic to infectious microorganisms, but also for the surrounding brain parenchyma, 
being correlated with neurodegenerative diseases like PD or AD (Block, 2008; Liu et al., 2002).  
 
1.2 Microglial Involvement in Neurodegenerative Diseases 
 
Microglial involvement in different neurological pathologies was vastly studied (Hanisch and 
Kettenmann, 2007; Neumann et al., 2008; Perry et al., 2010; Ransohoff and Perry, 2009; Wyss-
Coray and Rogers, 2012). Evidence of neurological pathology in which microglial activity is not 
involved is almost non-existent, as it was demonstrated with a variety of tools, ranging from 
cellular or animal models to positron emission tomography (PET)-evaluations of human patients 
(Perry et al., 2010). Compared with brain parenchyma acute injuries, neurodegeneration is a 
process in which microglia are becoming progressively activated, requiring longer periods of 
time to reach a fully activated state (Perry et al., 2007).   
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1.2.1 Nasu-Hakola Disease (NHD) 
 
Nasu-Hakola disease (NHD), also known as polycystic lipomembranous osteodysplasia with 
sclerosing encephalopathy (PLOSL), is a rare recessive human disorder characterized by 
presenile dementia and bone cysts (Bianchin et al., 2010; Kaneko et al., 2010a; Satoh et al., 
2011a). In the affected humans, the first symptoms of the disease are reported in the 3rd to 4th 
decade of life, when patients present frequent bone lesions (Kaneko et al., 2010a). Further on, 
the disease progresses towards a form of fronto-temporal dementia, leading to death in a 
couple of years (Bianchin et al., 2010). The main brain areas affected in NHD are the 
frontotemporal lobes and the basal ganglia, where neuronal loss together with astroglial cells 
proliferation and hypertrophy was reported (Kaneko et al., 2010a). However, the main 
characteristic of NHD is microglia activation (Bianchin et al., 2010; Satoh et al., 2011a).  
Today it is known that the molecular feature of NHD is loss of function mutations in the gene 
encoding the triggering receptor expressed in myeloid cells 2 (TREM2; Paloneva et al., 2002) or 
the gene encoding TREM2 associated adaptor molecule DNAX-activating protein of molecular 
mass 12 kDa (DAP12, also known as killer-cell activating receptor-associated protein, KARAP, or 
TYRO protein tyrosine kinase-binding protein, TYROBP; Kuroda et al., 2007; Paloneva et al., 
2000). Functional TREM2 and DAP12 were demonstrated to be required for the normal 
differentiation and function of myeloid linage cells osteoclasts (Paloneva et al., 2003). In the 
absence of TREM2, impaired bone resumption and inability of human NDH-derived osteoclasts 
to form multinucleated cells was reported (Cella et al., 2003), whereas DAP12 KO mice 
presented osteopetrosis and hypomyelinosis (Kaifu et al., 2003). Inside brain, Trem2/DAP12 
mRNA expression in mice is detected starting with E14 and colocalised with 
microglia/macrophages markers (Thrash et al., 2009). Mouse primary cell cultures evidentiated 
that the TREM2/DAP12 complex is involved in microglial removal of apoptotic neurons without 
inflammation (Takahashi et al., 2005). Based on these data, NHD is emerging as the prototype 
of the primary microglial disorder inside CNS (Bianchin et al., 2010). 
 
1.2.1.1 The TREM2/DAP12 Signaling Complex 
 
The first TREM family members (TREM1 and TREM2) were discovered in 2000, with functions 
related to the inflammatory response and associated with the already known DAP12 adaptor 
molecule (Bouchon et al., 2000). Besides TREM1 and TREM2, other molecules within the TREM 
family were described: TREM3 (functional gene in mice and pseudogene in humans) or trem-
like transcripts (TLT1 and TLT2; Allcock et al., 2003). In vertebrates, the TREM members present 
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conserved evolutionary structures similar in humans, mice, pigs, cows and chickens (Allcock et 
al., 2003). The general, the structure of TREMs is composed of an extracellular V-type 
immunoglobulin-like domain, a single transmembrane domain and a cytoplasmic domain 
(Colonna, 2003).  
 
Figure 1.2 – TREM2 and TREM1 expression and regulation in myeloid cells. TREM2 is expressed by 
monocyte-derived dendritic cells, immature osteoclasts and microglia. TREM1 is expressed in mature 
neurophiles, monocytes and macrophages (Colonna, 2003).  
TREM2 is considered an orphan receptor present on the surface of macrophages, immature 
dendritic cells, osteoclasts and microglia (Fig. 1.2; Colonna, 2003). The extracellular domain of 
murine TREM2 seems to be involved in recognizing polyanionic carbohydrate microbial 
products (Daws et al., 2001; N’Diaye et al., 2009; Quan et al., 2008). However, the specific 
molecular pattern recognized by TREM2 is not yet clear. The endogenous ligand of TREM2 is yet 
unknown, even though it was demonstrated that TREM2 is involved in vitro in microglial 
phagocytosis of apoptotic neurons without inflammation (Hsieh et al., 2009; Takahashi et al., 
2005). Nevertheless, these findings were not reproduced in vivo (Hsieh et al., 2009). The 
presence of an unidentified ligand on the surface of peritoneal and bone-marrow derived 
macrophages was observed using TREM2/Fc-chimera fusion proteins (Hamerman et al., 2006). 
Another study that used both murine and human TREM2 fusion proteins to study their binding 
to different cell types found that surface-exposed heat shock protein 60 (Hsp60) might act as a 
possible endogenous ligand for TREM2 (Stefano et al., 2009). However, within the study, mainly 
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tumoral cell lines were used as targets for TREM2 fusion proteins and thus the extracellular 
structures might have been already altered compared to the normal extracellular structures. 
TREM2, as the majority of the TREM family members, presents a short intracytoplasmic domain 
that is unable to generate signaling cascades (Fig. 1.3). Thus, TREM2 requires the recruitment of 
DAP12 for intracellular signaling (Bouchon et al., 2000; Colonna, 2003). TREM2-DAP12 
interaction is based on electrostatic bounds between a lysine residue in the transmebrane 
domain of TREM2 and an aspartatic acid residue in the structure of DAP12 (Bouchon et al., 
2000; Colonna, 2003). Based on immunoprecipitation, Takegahara and colleagues were able to 
show that TREM2 can form a heterocomplex together with PlexinA1, thus connecting PlexinA1 
with DAP12 signaling (Takegahara et al., 2006). Interestingly, the PlexinA1 KO animals also 
present deficits in osteoclast development similar to the ones found in DAP12 KO animals 
(Takegahara et al., 2006). Interactions between TREM2, DAP12 and other receptors, especially 
with the similar TREM1, were not yet described. 
 
Figure 1.3 – The TREM/DAP12 complex. Transmembrane domain of TREM receptors permits recruitment 
of DAP12 via charged interactions. DAP12 can form dimers based on an extracellular disulfide bond. Inside 
the cell, DAP12 presents an immunorecepor tyrosine-based activating motif (ITAM). The tyrosine residues 
(red Y) of ITAM can be phosphorylated, releasing intracellular signals following TREM2 activation. 
DAP12 is a molecule abundantly expressed by myeloid and natural killer cells (Lanier, 2009). 
Orthologues of the DAP12 encoding gene (TYROBP) were found throughout all vertebrates 
(from zebra fish to higher primates;(Lanier, 2009; Tomasello and Vivier, 2005). Proteins similar 
in function could be identified in lower species, as CED1 receptor in Caenorhabditis elegans and 
Draper protein in Drosophila (Ziegenfuss et al., 2008). DAP12 presents structural similarities 
with the common γ-chain (FcRγ, also known as FcεRIγ), and CD3ζ, all having a small extracellular 
domain containing cysteine residues that can form dimers via an extracellular disulfide bond 
and an immunoreceptor tyrosine-based activation motif (ITAM) inside the cell (Lanier, 2009). 
ITAM is a highly conserved sequence consisting of the amino acids D/ExxYxxL/I(x)6-8YxL/I, where 
‘x’ represents any amino acid (Fig1.3;(Hamerman et al., 2009; Ivashkiv, 2008).  
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Figure 1.4 – The general TREM/DAP12 signaling pathways. After receptor engagement, signaling inside 
the cell is generated via the ITAM domain of DAP12 adaptor molecule. The recruited spleen tyrosine 
kinase (Syk) acts on different substrates, leading to cytokines release via the mitogen activated protein 
kinase (MAPK) or nuclear factor kB (NFkB) activation, calcium signaling via the phospholipase Cγ (PLCγ), 
actin reorganization via the linker for activation of T cells (LAT) and RAC G-protein, or release of 
superoxide (O2·
-
) via activation of nicotinamide adenine dinucelotide phosphatase-oxidase (NADPH 
oxidase). The ITAM-related activation is inhibited by signaling via immunoreceptor tyrosine-based 
inhibitory motifs (ITIM) present in the structure of certain receptors (e.g. sialic acid-binding 
immunoglobulin-like lectins, Siglecs).  
The initial studies on the TREM2/DAP12 pathway by using agonistic TREM2 antibodies revealed 
increased intracellular calcium and activation of the ERK1/2 (Bouchon et al., 2001). However, 
no activation of ERK was detected when F(ab)’ antibodies were used, indicating that for TREM2-
mediated activation at least two receptors must be cross-linked (Bouchon et al., 2001). Further, 
the signaling cascade initiated by DAP12 after TREM2 engagement by a yet unknown ligand 
follows the usual DAP12 signaling pathway described in other reports (Lanier, 2009; Tomasello 
and Vivier, 2005; Turnbull and Colonna, 2007). Thus, it was first proven in natural killer cells 
(NKs) that the ITAM motif of DAP12 can be phosphorylated, leading to cellular activation via ζ-
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chain-associated protein kinase of 70 kDa (ZAP-70) and Syk kinases, a mechanism similar with 
that of the T- and B-cell antigen receptors via CD3ζ with which DAP12 presents structural 
resemblances (Lanier et al., 1998). Other studies contributed to identification of the DAP12 
canonical signaling pathway, as reviewed in(Turnbull and Colonna (2007): the recruitment of 
Syk to Dap12 ITAM motif leads to activation of phosphoinositol 3-kinase (PI3K), activation of 
phospholipase C gamma (PLCγ), together with phosphorylation of scaffolding proteins linker for 
activation of T cells (LAT) and non-T cell activation linker (NTAL) and ending with activation of 
protein kinase C (PKC) and ERK, intracellular calcium release and actin polymerisation. This 
succession of cellular events triggers cellular activation represented by functions like migration, 
phagocytosis or cytokines release (Turnbull and Colonna, 2007).  
Of note, TREM2 engagement, unlike TREM1, does not lead to IκBα activation with subsequent 
nuclear transposition of NfκB and release of proinflammatory molecules (Bouchon et al., 2001). 
On the contrary, in vitro studies of mouse microglial primary cultures showed that TREM2 
present anti-inflammatory functions (Takahashi et al., 2005). Shorthairpin RNA knockdown of 
TREM2 decreased clearance of apoptotic neurons and induced transcription of Tnfα and Nos2 
(Takahashi et al., 2005). 
ITAM signaling is under the control of  immunoreceptor tyrosine-based inhibitory motif (ITIM)-
bearing molecules (Barrow and Trowsdale, 2006; Hamerman et al., 2009). The ITIM sequence is 
represented by the amino acid sequence S/I/V/LxYxI/V/L, where ‘x’ represents any amino acid 
(Ravetch, 2000). ITIM sequences can be found in more than 36 different receptors, among 
them being sialic acid-binding immunoglobulin-like lectins, Siglecs (Staub et al., 2004). 
Receptors signaling via ITIM are implicated in supplying the inhibitory ‘off signals’ to the cell 
(Fig. 1.4). The inhibitory process is achieved by phosphorylation of the ITIM tyrosine by Src, 
leading to recruitment of phosphotyrosine phosphatases (PTP), such as SH2 domain containing 
phosphatase 1 (SHP1) or SH2 domain containing inositol phosphatase 1 (SHIP1), which in turn 
inhibits ITAM phosphorylation or activation of molecules downstream of ITAM (Peng et al., 
2010; Ravetch, 2000).  
 
1.2.2 Parkinson’s Disease (PD) 
 
PD is a progressive neurodegenerative disorder characterized by clinical symptoms like 
bradykinesia, tremor, rigidity and postural instability (Dauer and Przedborski, 2003). PD is only 
one type of the wider category of Parkinsonian disorders that have different molecular 
pathologies, but which all present loss of dopaminergic neurons projecting from the substantia 
nigra pars compacta (SNpc) to the putamen (Dickson, 2012). At cellular level, the main 
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characteristic of PD is the presence of α-synuclein aggregates, the so-called Lewy bodies (inside 
neuronal bodies) or Lewy neurites (inside dendrites). Different stages of PD were described 
based on the α-synuclein inclusions (Braak et al., 2003). 
Epidemiological studies on PD showed that 95% of the cases are sporadic with late onset, 
whereas only 5% are familial PD with genetic-determined early onset (Block and Hong, 2005). 
Familial PD is associated with mutations in several genes like the parkinson genes (PARKs), 
leucine-rich repeat kinase 2 gene (LRRK2) or α-synuclein gene (SNCA) (Kumar et al., 2012). 
Presenting a lower level of glutathion as buffer against the oxidative stress, dopaminergic 
neurons are a neuronal subpopulation that is more susceptible to the deleterious effects of 
microglial activation (Loeffler et al., 1994). Moreover, dopamine molecules and tyrosine 
hydroxylase (TH) involved in dopamine biosynthesis, are promoters of oxidative stress due to 
their chemical structure (Di Giovanni et al., 2012).  
 
Figure 1.5 – Mechanisms of neurodegeneration in PD. Microglia become activated by detecting 
extracellular α-synuclein, potentiating the NFkB pathway and leading to the release of proinflammatory 
molecules. Together with activation of the NADPH oxidase, inducible nitric oxide synthase (iNOS) and 
cyclooxigenase 2 (COX2), toxic molecules acting on dopaminergic neurons are released inside the brain 
parenchyma. These molecules amplify microglial activation and also induce a toxic response from 
astrocytes, further contributing to the neurodegenerative process (Glass et al., 2010). 
The involvement of microglia in the pathology of PD is well documented (Fig1.5; Block and 
Hong, 2005; Cunningham, 2013; Dauer and Przedborski, 2003; Glass et al., 2010; Hirsch et al., 
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2012; Perry, 2012). There is a common scientific consensus that microglia are activated by the 
α-synuclein aggregates leading to the release of a broad range of proinflammatory molecules. 
In vivo models of PD are characterised by microglial release of Il1β, Il2, Il6, Tnfα or Tgfβ as 
reponse to α-synuclein (Glass et al., 2010; Roodveldt et al., 2008). These results confirmed 
previous studies that mentioned similar cytokine patterns in brains affected by PD (Mogi et al., 
1994a, 1994b). In rat and mouse primary cultures microglia contribute to extracellular 
clearence of α-synuclein via phagocytosis, followed by NADPH oxidase-mediated production of 
O2·
- (Zhang et al., 2005). Indeed, Hunot and colleagues have previously reported increased level 
of NADPH oxidase and inducible nitric oxide synthase (iNOS) in PD brains (Hunot et al., 1996).  
 
1.2.2.1 Animal Models of PD 
 
Microglial implication in PD was widely studied in different in vivo and in vitro models. 
Generally, mouse models were used to reproduce human diseases due to their neuronal 
physiology and gene-associated homology (Waterston et al., 2002). A broad range of mouse 
model techniques were used to better characterise the human PD condition, leading to 
progress in the understanding of some aspects of the disease. However, to this date no 
generally valid model recapitulates the entire constellation of PD associated symptoms and 
dysfunctions (Lee et al., 2012; Pickrell et al., 2013). To study the genetic aspect of PD, knock-out 
(KO), knock-in or conditional transgenic animals were generated for genes implicated in PD. For 
example, the expression of human α-synuclein in mice was discovered to promote formation of 
abnormal axons and terminals, age-related impairments in motor coordination and age-related 
reduction in dopamine content and metabolites (Richfield et al., 2002). A similar phenotype 
was observed in another study using conditional human α-synuclein mice under a specific 
neuronal promoter (Nuber et al., 2008). Other PD mouse models have used induction of 
transgenes via viruses stereotactically injected inside the brain. Thus, injections of expressing 
viruses into the striatum permitted in vivo identification of LKRR2 enzyme inhibitors, thus 
efficiently protecting the nigrostriatal system against degeneration (Lee et al., 2010).  
Toxicological studies proved the specificity of dopaminergic degeneration, also pointing to 
microglial involvement in the process (Bezard et al., 2013; Dauer and Przedborski, 2003; Miller 
et al., 2009). Thus, neurotoxins like 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), as well as other toxic compounds (e.g. roteonone, paraquat) were 
shown to lead to a PD-like phenotype.  
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1.2.2.1.1 Lipopolysaccharide (LPS)-triggered Dopaminergic Degeneration 
 
Lipopolysaccharides (LPS) were identified as an in vivo experimental inducer of dopaminergic 
neurons degeneration, similar with the one observed in PD (Gao et al., 2002; Qin et al., 2007). 
LPS is a compound found on the outer membrane of gram-negative bacteria. The general 
structure of LPS is composed of an O-antigen polysaccharide chain core composed of outer and 
inner polysaccharides and the so called lipid A, consisting of a diglucosamine to which six fatty 
acid chains are attached (Erridge et al., 2002).  
 
Figure 1.6 – Toll like receptor 4 (TLR4) signaling patway. Upon ligand (e.g. LPS) engagement, TLR4 
activates the myeloid differentiation primary response protein 88 (MyD88)-dependent and the TIR-
domain-containing adaptor-inducing interferon-β (Trif)-dependent pathways. MyD88 leads to secretion of 
proinflammatory cytokines via activation of nuclear factor k-light-chain-enhancer of activated B cells 
(NFkB) nucear transposition and activation protein-1 (AP-1), whereas Trif-mediated pathway contributes 
also to the release of proinflammatory cytokine via NFkB and AP-1 activation, but additionally also to the 
secretion of type I interferons (IFN; modified after(Kawai and Akira, 2006). 
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LPS driven inflammation was exhaustively studied both in vitro and in vivo, the signaling 
pathway released by LPS being well described (Fig. 1.6). LPS is recognized by a complex formed 
by the toll like receptor 4 (TLR4; CD284) and the myeloid differentiation factor 2 (MD2) in 
cooperation with CD14 (Miller et al., 2005; Park et al., 2009). After activation, the signaling 
cascades can follow a myeloid differentiation primary resoponse protein 88 (MyD88)-
dependent or MyD88-independent pathway, leading to release of inflammatory cytokines, 
interferon γ (IFNγ) and IFN-inducible proteins (Kawai and Akira, 2006; O’Neill et al., 2013). LPS 
leads to activation of immune cells, including microglia (Kettenmann and Hanisch, 2011).  
Among the effects of in vivo LPS administration were reported circulatory shock, disseminated 
intravascular coagulation and damages to numerous organs such as CNS, liver, kidney, heart, 
gastrointestinal tract and lungs, ending with shock and death (Hasegawa et al., 1999) 
To study the involvement of LPS in dopaminergic degeneration in vivo, different models of LPS 
application were used, ranging from direct intranigral injection to systemical application of LPS 
(reviewed in Cunningham, 2013; Dutta et al., 2008). Single injections of LPS directly into the SN 
of rodents led to increased dopaminergic neurons loss together with decreased levels of 
dopamine 21 days after the injection (Castaño et al., 1998). Studies on the kinetics of 
dopaminergic neuron loss showed that microglial cells are promptly activated by intracranial 
LPS application, increasing their production of inflammatory cytokines (Arai et al., 2004) and 
ROS (Qin et al., 2004) with loss of dopaminergic neurons detected only a couple of weeks after 
injection (Fig. 1.7;(Liu, 2006; Liu et al., 2000). Similar pattern of microglia activation and 
dopaminergic degeneration was observed in rats supranigrally infused with LPS over a 2 week 
period (Gao et al., 2002). Other studies have shown that dopaminergic degeneration reaches an 
irreversible plateau 8 weeks after LPS application based on LPS concentration, whereas 
microglial activation gradually subsides (Iravani et al., 2005; Liu, 2006). Injections with LPS into 
the globus pallidus (part of the basal ganglia involved in movement control) led to loss of SNpc 
dopaminergic neurons in particular in older animals compared with young ones (Zhang et al., 
2005). The model of direct LPS injection inside CNS provided in vivo evidence of higher SNpc 
dopaminergic neuronal sensitivity to the LPS application compared with the SN γ-aminobutyric 
acid signaling neurons (GABAergic neurons) or even dopaminergic neurons of the ventral 
tegmental area (Castaño et al., 1998; Gao et al., 2002). 
 
Based on the evidence of communication between the peripheral immunity and the CNS local 
immunity, systemic inflammation was hypothesized to induce neurodegeneration (Galea et al., 
2007; Perry et al., 2010). Indeed, Qin and colleagues showed that one systemic intraperitoneal 
(i.p.) application of 5 µg LPS per gram body weight (gbw) leads not only to dopaminergic 
neuronal loss, but also that the process is progressive (Qin et al., 2007), unlike that of direct 
Introduction 
 
17 
 
intranigral LPS application. However, the dopaminergic loss was shown to be significant only 7 
months after LPS i.p. injection (Qin et al., 2007).  
 
Figure 1.7 – Kinetics of LPS-triggered dopaminergic loss in animal models. a – A single intranigral 
injection of LPS elicits a fast response in microglia (red line) and astrocytes (green line), with dopaminergic 
loss (black line) reaching a plateau phase in a couple of months after treatment; b – Infusing LPS 
intranigrally for a period of several days decreased the time required to obtain dopaminergic neuronal 
loss (modified from(Liu, 2006). 
Dopaminergic degeneration was also explored in relation to LPS exposure in fetal stages. Pups 
exposed to LPS in utero and again a second time after birth, presented specific and significant 
reduction in the number of SNpc dopaminergic neurons and of striatal dopamine compared 
with controls (Ling et al., 2006). Moreover, prenatal exposure to LPS increases the susceptibility 
of dopaminergic degeneration after challenges with other toxins, like Ling and collegues 
observed in a rotenone study (Ling et al., 2004).  
 
1.2.3 Alzheimer’s Disease (AD) 
 
AD is the most common age-related neurodegenerative disease, characterized by progressive 
loss of memory and cognitive functions (LaFerla et al., 2007).  The first severe 
neuropathological changes can be observed in the hippocampus, followed by the associated 
cortical and subcortical structures (Götz and Ittner, 2008). Even though detailed cellular 
pathology of AD was reported from the 1900s as being represented by extracellular and 
intracellular depositions inside the brain, the chemical composition of these depositions was 
not identified until the 1980s. Thus, the extracellular structures (or ‘plaques’) were decribed as 
18 
 
being composed of small peptides called amyloid-β (Aβ; Glenner and Wong, 1984), whereas the 
neurofibrillary tangles (NFT) found inside neurons were described as consisting of aggregated 
and hyperphosphorylated tau protein (Grundke-Iqbal et al., 1986).  
Aβ is generated via successive cleavage of the amyloid precursor protein (APP) via successive 
contribution of specific enzymes, generally termed ‘secretases’ (Fig. 1.8). The processing of APP 
can follow either a normal non-amyloidogenic pathway (the non-pathological pathway) or an 
amyloidogenic pathway (leading to Aβ pathological accumulation; Citron, 2004; LaFerla et al., 
2007).  
 
Figure 1.8 – Amyloid precursor protein (APP) processing. Left - The non-amyloidogenic pathway is 
started by the action of α-secretase on APP that releases soluble the αAPPs fragment and the C83 
membrane fragment. C83 is further processed by γ-secretase, generating the non-toxic p3 fragment; 
Right - The amyloidogenic pathway is initiated by β-secretase cleavage of APP that releases the βAPPs 
fragment and he C99 membranare fragment. C99 can be cleaved via action of γ-secretase, generating Aβ 
fragments (Citron, 2004). 
The non-amyloidogenic pathway requires the initial release of sAPPα N-domain and of C83 C-
terminal fragment from APP by the action of α-secretase (a disintegrin- and metalloprotein-
family enzyme, ADAM;(Allinson et al., 2003). C83 can be subsequently cleaved by γ-secretases 
releasing the shorter non-toxic fragment p3 (Haass and Hung, 1993). Of note here is that the γ-
secretase is a multi-subunit enzyme formed of presenilin (PS), nicastrin, anterior pharynx-
defective 1 (APH1) and presenilin enhancer 2 (PEN2;(Sisodia and St George-Hyslop, 2002). 
Mutations in γ-secretase substructures can lead to certain pathological conditions as discussed 
further.  
The pathological amyloidogenic pathway of APP processing leads to release of Aβ fragments of 
different sizes and with different toxicities via a mechanism that requires an initial cleavage 
step performed by β-secretase (known also as β-site APP-cleaving enzyme 1, BACE1; Sisodia 
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and St George-Hyslop, 2002). After β-secretase processing of APP, soluble sAPPβ and C99 C-
terminal fragments are released. C99 is further processed by γ-secretase which can cleave at 
different sites and thus releasing Aβ fragments of different sizes. The Aβ with 40 amino acid 
residues (Aβ40) is the most abundant product of C99 processing (LaFerla et al., 2007). However, 
it has been observed that Aβ42 is found in great quantity in AD plaques (Braak and Braak, 1991) 
and that Aβ42 is highly toxic for the brain parenchyma (reviewed in Benilova et al., 2012). 
Moreover, it was proven that Aβ42 has a high tendency to aggregate into oligomers or fibrils 
both in vitro (Barrow and Zagorski, 1991) and in vivo (McGowan et al., 2005).  
Unlike AD plaques that are constituted of Aβ aggregates, the NFT lesions present aggregates of 
microtubule-associated protein τ (tau). Under normal physiological conditions, tau presents 
several phosphorylation sites and is implicated in the stabilization of microtubules inside the 
axons (Ballatore et al., 2007). However, under pathological conditions, tau was found in a 
hyperphosphorylated state that contributes to its detachment from microtubules, leading to 
destabilization of the entire neuronal scaffold system (Götz and Ittner, 2008). Based on 
postmortem NFT depositions, AD pathology was divided into 6 different stages (Braak and 
Braak, 1991). There are different theories trying to explain the link between the presence of 
both Aβ and tau deposits in the AD diseased brain. However the results are so far inconclusive.  
Studies on the etiology of AD have indentified an early onset of the disease (EOAD, also known 
as familial AD, FAD) or a late onset AD (LOAD, also known as sporadic AD, SAD). EOAD has a 
higher incidence between 60 and 65 years of age (Bertram and Tanzi, 2008) and accounts for 
only 1% of the total AD cases (Götz and Ittner, 2008). EOAD was described as being caused by 
autosomal-dominant mutations in ether the APP encoding gene (APP) or in the γ-secretase 
subunits PS1 (PSEN1) or PS2 (PSEN2; Bertram and Tanzi, 2008). LOAD on the other hand does 
not present any autosomal causality, but a high allele diversity across different genes (Bertram 
and Tanzi, 2008). However, excepting the age of onset (above 65 years), the clinical and 
histopathological characteristics of LOAD cannot be distinguished from EOAD (Götz and Ittner, 
2008). Genome wide association studies (GWAS) have identified several clustering patterns 
pointing towards immunity (CLU, CR1, CD33, EPHA1, MS4A4A/MS4A6A), lipid processing (APOE, 
ABCA7) or endocytosis (PICALM, BIN1, CD2AP) involvement in LOAD (reviewed in Bettens et al., 
2013). Besides the ε4 allele of the apolipoprotein E gene (APOE), no other gene has shown high 
LOAD incidence risk (Bertram et al., 2007; Neumann and Daly, 2013). Recently, TREM2 gene has 
been described by two individual groups as having similar odds ratio with that of APOE 
(Guerreiro et al., 2013; Jonsson et al., 2013).    
Microglial role in AD is still under debate with studies pointing towards a detrimental role of 
microglia in AD pathology via activation and release of toxic factors (Fig. 1.9) or with studies 
providing evidence supporting microglia involvement in the clearance of Aβ plaques. Initial 
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studies on the cellular pathology of AD have observed clustering of microglia around the 
plaques, proposing a direct link between microglial cells and AD pathology (Griffin et al., 1989; 
Perlmutter et al., 1990). Electron microscopy studies have proven the microglial uptake of Aβ 
inside AD brains (D’Andrea et al., 2004). Mouse studies confirmed the Aβ up-take, providing 
evidence that microglia migrate towards Aβ plaques (Bolmont et al., 2008; Meyer-Luehmann et 
al., 2008) and internalize Aβ at least partially via a macropinocytosis mechanism (Mandrekar et 
al., 2009). However, other several in vitro studies showed that in a proinflammatory 
environment, microglia are unable to take up or degrade the internalized Aβ (Koenigsknecht-
Talboo and Landreth, 2005; Zelcer et al., 2007), leading to the idea of long-term use of non-
steroidal anti-inflammatory drugs for the treatment of AD (Mandrekar and Landreth, 2010). 
Many receptors were postulated to be involved in Aβ recognition and uptake, like TLRs and the 
co-adaptor molecule CD14 (Liu et al., 2005), a multi-component structure formed of CD36, 
integrin α6β1, integrin-associated CD47 and scavenger receptor A (Bamberger et al., 2003), or 
complement components (Koenigsknecht and Landreth, 2004). Subsequent to microglial Aβ 
internalization, Aβ is trafficked towards distinct acidified lysosomes (Bolmont et al., 2008; 
Majumdar et al., 2007; Mandrekar et al., 2009). Interestingly, inability of lysosomal proteolysis, 
in which PS1 seems to play an important role, was correlated with AD (Lee et al., 2010). 
 
Figure 1.9 – Mechanisms of Aβ-mediated neurodegeneration in AD. Microglia can recognize Aβ plaques 
by a yet not fully known mechanism that leads to activation of the NFkB pathway and releasing 
proinflammatory molecules. These molecules can contribute to activation of microglia and astrocytes, 
resulting in release of toxic molecules. Microglia can present also protective effects by contributing to Aβ 
clearance (Glass et al., 2010). 
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1.3 Objectives of the Thesis 
 
 
 
 
Microglial cells were previously described as presenting both neuroprotective and neurotoxic 
functions both in vitro and in vivo. However, the intimate mechanisms involved in the 
development of microglial-mediated neuropathological conditions are not fully understood. 
The present thesis proposes to address these blank spots of microglial physiology.  
The first aim of the thesis was to explore the impact of triggering receptor expressed on  
myeloid cells 2 (TREM2) deficiency in a mouse model of Nasu-Hakola disease, which represents 
the prototype of primary microglial disorder inside CNS (Bianchin et al., 2010). Previously, 
TREM2 was described as being involved in microglial phagocytosis of apoptotic neurons and 
immunosupression, its absence leading to increased levels of proinflammatory cytokines 
(Takahashi et al., 2005). In view of this knowledge, it was hypothesised that the absence of 
TREM2 in microglia should determine an enhanced proinflammatory milieu inside parenchyma, 
with detrimental consequences for the brain and the organism. 
The second aim of the thesis was to investigate the involvement of microglia in bacterial toxin 
lipopolysaccharide (LPS)-triggered dopaminergic degeneration. Studies on both in vitro and in 
vivo models of parkinsonism have reported sensitivity of dopaminergic neurons to LPS, in  
correlation with microglial activity (Cunningham, 2013; Dutta et al., 2008). Within the present 
thesis, two LPS treatment paradigms of mice were compared via systems biology methods to 
identify potential genes involved in the process of microglial-mediated dopaminergic 
neurodegeneration and to validate them in an in vivo model. 
The third aim of the thesis was to examine the implications of the TREM2 adaptor molecule 
DNAX-activating protein of molecular mass 12 kDa (DAP12) in late onset Alzheimer’s disease 
based on a genome-wide association study that identified DAP12 as key regulator of the 
disease (Zhang et al., 2013). Microglial cells overexpressing functional and non-functional 
DAP12 were assessed in regard with their amyloid-β internalization capacity and other DAP12-
associated cellular functions. 
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2. Materials and Methods 
 
 
 
2.1 Mice 
 
For in vivo experiments, different lines of mice were used (Table 2.1). C57BL/6J (referred 
hereafter as BL6 mice) and B6;129S4-C3tm1Crr/J (referred as C3 KO mice in text) were purchased 
from Charles River (Sulzfeld, Germany). The C3 KO mice were generated by targeted deletion of 
nucleotides 1850-2214 within the mouse C3 coding region (AA 620-741, pro-C3 numbering). 
The B6.129P2-TREM2tm1cln mice (referred hereafter as TREM2 KO mice) were kindly provided by 
Prof. Dr. Marco Colonna (Department of Pathology and Immunology, Washington University 
School of Medicine, USA). They were generated by deleting a portion of the mouse TREM2 
receptor trans-membrane and cytoplasmic domains (encoded by exons 3 and 4) and 
backcrossed on C57BL/6J background (Turnbull et al., 2006).  
The mice were housed and bred in the institute’s animal facility, in a controlled specific 
pathogen free (SPF) environment, with 12 hours light/night cycles and water and food ad 
libitum. The mice were subsequently intercrossed at least once every 8-10 generations with 
new BL6 mice to prevent genetic drift, in accordance with the Banbury Conference 
recommendations (Silva et al., 1997). All experiments were conducted in accordance with local 
animal ethics procedures.  
Table 2.1 Mouse lines 
Mouse line Full Name Provider Registered Office/Contact 
BL6  C56BL/6J Charles River Sulzfeld, DE 
C3 KO B6;129S4-C3tm1Crr/J Charles River Sulzfeld, DE 
TREM2 KO B6.129P2-TREM2tm1cln  Prof.Dr.Marco Colonna Washington University, USA 
 
2.1.1 Mice Genotyping 
 
Mice were genotyped from tissue of collected ear markings preserved at -80°C until used. For 
genotyping, tissue samples, primers (Table 2.2) and REDExtract-N-AmpTM Tissue Polymerase 
Chain Reaction (PCR) Kit [for producers and/or details of products, see the 2.6 subchapter] 
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were used following genotype-specific programs (Table 2.3). The genotyping PCR products were 
loaded in a 1.5-2% agarose gel, run under 100-130 V and visualized by using a ChemiDoc Gel 
Imaging System. 
Table 2.2 Genotyping primers 
Mouse 
line 
Forward Primer (5‘→3‘) Reverse Primer (5‘→3‘) Expected length 
TREM2 KO I.CCAGCAGTGGCCTAAATGGA 
II.CTTATGTGGAAGAGCTCATCG
GG 
TCTGACCACAGGTGTTCCCG 
 
WT: 337 base pairs (bp) 
KO: 256 bp 
hetero: both bands 
C3 KO ATCTTGAGTGCACCAAGCC I.GGTTGCAGCAGTCTATGAA
GG 
II.GCCAGAGGCCACTTGTGTA
G 
WT: 350bp 
KO: 500bp 
hetero: both bands 
 
Table 2.3 Genotyping programs                                
TREM2 KO mice 
   
C3 KO mice 
Temperature Time Cycles 
   
Temperature Time Cycles 
94°C 180 s  
   
94°C 180 s  
94°C 45 s  
30x    
94°C 20 s  
12x 58°C 45 s 
   
64°C 30 s 
72°C 45 s 
   
72°C 35 s 
72°C 300 s  
   
94°C 20 s  
25x 4°C ∞  
   
58°C 30 s 
   
   
72°C 35 s 
   
   
72°C 120 s  
      
   
10°C ∞  
 
2.1.2 LPS Treatment Schemes 
 
To induce systemic inflammation in mice, three months old male animals were intraperitoneally 
(i.p.) injected with lipopolysaccharide (LPS) or with 100 µL phosphate buffer saline (PBS) vehicle 
as control. For single treatment, animals were injected once with 4 µg LPS per gram body 
weight (gbw) or vehicle and sacrificed in the 5th or 19th day since the start of the treatment (Fig. 
2.1). For repeated treatment, four injections in consecutive days, with 1 µg LPS/gbw or vehicle 
were performed and the mice were analysed in the 5th or 19th day since the start of the 
treatment (Fig. 2.1). 
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Figure 2.1 – Experimental schemes of single and repeated LPS treatments of mice analysed on the 
experimental day 5 or 19. Mice were intraperitoneally (i.p.) injected either once with 4 µg 
lipopolysaccharides (LPS) per gram body weight (gbw, single treatment, top), or with 1 µg/gbw on 
four consecutive days (repeated treatment, bottom) before analysis.  
 
2.1.3 Tissue Collection and Storage 
 
For brain and/or plasma collection, mice were first deeply anesthetized i.p. with 0.8-1 mL 
avertin (1.25% v/v; Table 2.4).  
 
Table 2.4 Avertin (2,2,2-tribromoethanol) solution protocol 
Step Mouse line Quantity Provider Registered Office 
1. Mix preparation  
 Avertin 50 g Sigma-Aldrich München, DE 
 t-amyl alcohol  
(2-methyl-2-butanol) 
31 mL Sigma-Aldrich München, DE 
2. Incubate overnight with shaking, in dark, at room temperature 
3. Filter (0.22 µm) & store  at 4°C 
4. Working concentration 1.25% (v/v) in PBS 
 
Plasma was collected from aortic blood preserved on heparin and centrifuged 1500xg to 
remove the blood cells. Aliquotes were stored at -20°C until used. 
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For RNA extraction, mice were intracardially perfused with 20-30 mL PBS, the brains were 
collected and processed as mention in subchapter 2.3.1.1.  
For immunohistochemistry, mice were intracardially perfused with 20-30 mL PBS, followed by 
20-30 mL 4% paraformaldehyde (PFA). The PFA-fixed brains were collected, stored at 4°C for 
another 24h in 4% PFA before immersing in 30% glucose (with 0.1% sodium azide) and storing 
at 4°C. After 24-48h in the glucose solution, the brains were placed in cryomolds, covered in 
TissueTek® medium, frozen and processed as mentioned in subchapter 2.1.3.1. 
 
2.2 Cell Cultures 
2.2.1 Primary Cell Cultures 
2.2.1.1 Microglia Primary Cell Cultures 
 
Primary microglia cells (Table 2.5) were isolated from newborn mice (Yiner Wang and 
Neumann, 2010). In this regard, P3 brains from BL6 or TREM2 KO mice were isolated, cleaned 
of meninges and dissociated before plating into cell culture flasks precoated with poly-L-lysine. 
The cells were kept in primary microglia medium (Table 2.5), in a 37°C incubator, under 5% CO2 
and 95% humidity. The cell culture medium was changed weekly and after 3-4 weeks, the 
primary microglia were detached by vigorous shaking, counted and used in further 
experiments. 
 
2.2.1.2 Neuronal Primary Cell Cultures 
 
Hippocampi of E14 BL6 mice were isolated, mechanically dissociated and seeded in poly-L-
lysine coated chamber slides at a density of 2.5 x 105 cells/mL and kept in a 37°C incubator, with 
5% CO2 and 95% humidity (Y Wang and Neumann, 2010). Cells were kept in neuronal media 
(Table 2.5) for at least 5 days before they were used in experiments.  
 
2.2.2 Cell Lines  
 
Embryonic stem cell derived microglia (ESdM) were generated in the lab based on a 5-steps 
differentiation protocol (Beutner et al., 2010). These cells have been shown to present great 
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similarity to primary microglial cell cultures (Beutner et al., 2013, 2010). Human Embyonic 
Kidney 293FT (HEK293FT) cell line was purchased from Invitrogen. 
Table 2.5 Primary cells  
Cell  Media Provider/Origin 
Primary microglia Primary microglia medium 3 days old mice (P3) 
Primary neurons Primary neurons medium 14 days mouse embryos (E14) 
 
Table 2.5 Primary cell culture media  
Medium Component Quantity Manufacturer Reg.office 
Primary microglia medium 
 Basal Medium Eagle (BME) 500 mL Gibco, LifeTechnologies  Darmstadt, DE 
 Fetal Calf Serum (FCS) 50 mL PAN Biotech GmbH Aidenbach, DE 
 L-Glutamine  5 mL Gibco, LifeTechnologies  Darmstadt, DE 
 D-Glucose 45% 5 mL Sigma-Aldrich München, DE 
 Penicillin/Streptomycin 5 mL Gibco, LifeTechnologies  Darmstadt, DE 
Primary neuronal medium 
 BME 500 mL Gibco, LifeTechnologies  Darmstadt, DE 
 B-27 supplement 10 mL Gibco, LifeTechnologies  Darmstadt, DE 
 D-Glucose 45% 5 mL Sigma-Aldrich München, DE 
 FCS 50 mL PAN Biotech GmbH Aidenbach, DE 
2.2.2.1 General Cell Lines Handling  
 
Cells (Table 2.6) were thawed fast and washed by centrifugation (1500xg, 3 minutes) within 
appropriate cell culture media (Table 2.7). The pellet was resuspended, plated in new media 
and kept in an incubator with 5% CO2, 95% humidity and 37°C. When reaching cca. 80% 
confluency, cells were detached either mechanically (scraping) or chemically (Trypsin/EDTA 
0.25%, 3-5 minutes), centrifuged (1500xg, 3 minutes) and plated in a new culture dish.  
For long time storage, after detaching and centrifugation, cells were resuspended in 1 mL 
appropriate freezing media (Table 2.7) and placed in cyrotubes. After ≥ 24 h of storage in an 
isopropanol containing tank at -80°C for slowly freezing, the cells were moved to liquid N2 for 
long time storage. 
Table 2.6 Cell types 
Cell  Full name Media Provider/Origin Registered Office 
ESdM Embryonic Stem cells 
derived Microglia 
N2 medium (Beutner et al., 
2010) 
 
HEK 293FT Human Embryonic Kidney 
293FT  
MEF medium Invitrogen, Life 
Technologies 
Darmstadt, DE 
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Table 2.7 Cell culture media  
Medium Component Quantity Manufacturer Registered 
office 
N2 medium 
 Dulbecco’s Modified Eagle Media 
(DMEM) + Factor 12 (1:1)  
+ L-glutamine, + 15 mM HEPES 
500 mL Gibco, 
LifeTechnologies  
Darmstadt, DE 
 N2 supplement 5 mL Gibco, 
LifeTechnologies  
Darmstadt, DE 
 L-Glutamine  1.2 mL Gibco, 
LifeTechnologies  
Darmstadt, DE 
 D-Glucose 45% 1.7 mL Sigma-Aldrich München, DE 
 Penicillin/Streptomycin 5 mL Gibco, 
LifeTechnologies  
Darmstadt, DE 
MEF  Medium  
 (DMEM + L-glutamine, - sodium 
pyruvate, + 4.5 g/L D-glucose 
500 mL Gibco, 
LifeTechnologies  
Darmstadt, DE 
 L-Glutamine  5 mL Gibco, 
LifeTechnologies  
Darmstadt, DE 
 Sodium Pyruvate 100 mM 5 mL Gibco, 
LifeTechnologies  
Darmstadt, DE 
 Non-essential amino-acids 10 mM 5 mL Gibco, 
LifeTechnologies  
Darmstadt, DE 
 FCS 50 mL PAN Biotech 
GmbH 
Aidenbach, DE 
 Penicillin/Streptomycin 5 mL Gibco, 
LifeTechnologies  
Darmstadt, DE 
Cell culture freezing medium 
 Appropriate cell culture media 40%   
 Dimethyl sulfoxide (DMSO) 99% 10% Sigma-Aldrich München, DE 
 Fetal calf serum (FCS) 50% Sigma-Aldrich München, DE 
 
2.2.3 Microglia-Neurons Cocultures  
 
For obtaining microglia-neurons cultures, ESdM cells were detached from dish, counted and 
resuspended in primary neuronal culture (Table 2.5). Half volume of medium from the primary 
neurons was removed and new ESdM-containing medium was added (5:1 microglia:neurons). 
The ESdM cells were left to adhere for at least 3 h before experiments. 
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2.2.4 Cellular Functional Assays 
2.2.4.1 Phagocytosis Assay 
 
For obtaining fibrillar amyloid-β (Aβ), synthetic human Aβ peptide amino acid 1-42 (1 mg/mL) 
was incubated in PBS for at least 3 days at 37°C to obtain fibrillar Aβ. Microglia (ESdM) cells 
were treated with 10 μg/mL biotinylated Aβ or 500 μg/mL biotinylated albumin for 1 h at 37°C. 
Cells were fixed and the up-taken biotinylated material was immunostained with streptavidin-
Cy3 (2 µg/mL; see subchapter 2.4.3 for a detailed staining protocol). Percentage of cells having 
phagocytosed Aβ or albumin was analysed in 5-10 randomly selected areas per condition by 
confocal microscopy, 3D reconstruction and ImageJ software.  
 
2.2.4.2 Detection of Superoxide Production  
 
Cells were seeded at a density of 40,000 cells per well in chamber slides and were stimulated 
for 30 minutes with 10 μg/mL fibrillary Aβ, 500 μg/mL zymosan A, 500 μg/mL albumin or PBS 
control. To detect superoxide production culture medium was replaced by Krebs-HEPES-buffer 
(Table 2.8) and then incubated with 30 μM DHE for 15 minutes or 30 minutes for the Aβ group, 
at 37°C. Cells were washed three times with Krebs-HEPES-buffer, fixed with 4 % PFA and 
mounted on cover slides with Mowiol 4-88. A number of 6 images per experimental group (30-
60 cells per experimental group) were scanned using an Olympus IX81 inverted confocal 
microscope and quantified using the ImageJ software. 
Table 2.8 Krebs-HEPES Buffer 
Component Concentration  Manufacturer Registered Office 
HEPES* 8.3 mM Carl Roth GmbH  Karlsruhe, DE 
NaCl 130.0 mM Sigma-Aldrich München, DE 
KCl 5.6 mM Sigma-Aldrich München, DE 
CaCl2 2.0 mM Sigma-Aldrich München, DE 
MgCl2 0.24 mM Sigma-Aldrich München, DE 
Glucose 11.0 mM Carl Roth GmbH  Karlsruhe, DE 
* 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
 
2.2.4.3 Neurites Length Analysis 
 
For analysis of neurite length, preincubated fibrillar biotinylated Aβ (10 μg/mL) was added to 
the primary neuron culture or ESdM-neuron co-culture for 24 hours, after which the cells were 
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fixed and immunostained (see 2.4.3). Neurons were visualized using anti-β III-tubulin (1 µg/mL) 
and Cy3-conjugated secondary antibody (2 µg/mL; see subchapter 2.4.3 for a detailed staining 
protocol). For the detection of Aβ, Cy5-streptavidin (2 µg/mL) was used. Images (5-10 randomly 
selected areas in each experimental group) were collected via laser scanning confocal 
microscope. The mean length of βIII-tubulin positive neurites was quantified using the ImageJ 
software and NeuronJ plugin. 
 
2.3 Molecular Biology 
2.3.1 PCR, RT, sqRT-PCR 
2.3.1.1 RNA Isolation and RT 
 
Cells or brain tissue (for brain collection see subchapter 2.1.3) were homogenized in 0.5-1 mL 
QIAzol using a TissueLyser homogenizer. Subsequently, RNA was isolated either using the 
RNeasy® Lipid Tissie Kit, RNeasy® Mini Kit after manufacturer’s specifications or a modified 
phenol-chloroform based method (Table 2.9).  
Table 2.9 RNA isolation (modified phenol-chloroform method) 
Step Quantity Sonditions Time 
Adding QIAzol to tissue/cells 1 mL   
Lysis via TissueLyser (50Hz)  Room temperature 3 min 
Incubation with chloroform + 200 µL Room temperature 3 min 
Centrifugation  13,000xg, 4°C 15 min 
Collection of the aqueous phase    
Incubation with isopropanol 1:1 (vol) -20°C Overnight 
Centrifugation  13,000xg, 4°C 15 min 
Collection of the sediment    
Mixing with 70% ethanol + 300 µL   
Centrifugation  13,000xg, 4°C 15 min 
Collection of the sediment, drying and resuspension in 50 µL RNase free water 
 
The RNA content was measured using a Nanodrop spectrophotometer. RT of 50 µg total RNA 
was performed using SuperScript III reverse transcriptase and hexameric random primers (Table 
2.10).  
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Table 2.10 Reverse Transcription 
Prepare RT Mix (I) Component Amount Manufacturer Registered office 
 RNA 11 µL (50 µg)   
 Hexanucleotids 
(mM) 
1 µL Roche Grenzach-Wyhlen, DE 
 dNTPs (mM each) 1 µL Paqlab Erlangen, DE 
 Start RT  
Program 
Temperature Time   
 65°C 5 min   
 4°C 1 min   
 4°C pause   
Add RT Mix (II) Component Amount Manufacturer Registered office 
 Forwards Strand 
Buffer 5x 
4 µL Invitrogen, 
LifeTechnolgies 
GmbH 
Darmstadt, DE 
 DTT (0.1 M) 2 µL Invitrogen, 
LifeTechnolgies 
GmbH 
Darmstadt, DE 
 SuperScript III 1 µL Invitrogen, 
LifeTechnolgies 
GmbH 
Darmstadt, DE 
 Continue RT  
Program 
Temperature Time   
 25°C 5 min   
 55°C 1h   
 70°C 15 min   
 4°C ∞   
 
2.3.1.2 sqRT-PCR 
 
For evaluating transcriptional levels, sqRT-PCR was performed using 1 µL cDNA diluted 1:10, 
SYBR GreenER qPCRSuperMix Universal, and 400 nM mouse primers (Table 2.11) into a final 
reaction volume of 25 µL.  
Table 2.11 sqRT-PCR Primers 
Gene Accession No. Forward Primer (5‘→3‘) Reverse Primer (5‘→3‘) 
C1q NM_011795.2 CTGCAAGAACGGCCAGGTGC AGCCACGGATGAAAAGGGGTG 
C3 NM_009778.2 TAGTGCTACTGCTGCTGTTGGC GCTGGAATCTTGATGGAGACGCTT 
C4 NM_009780.2 TGGAGGACAAGGACGGCTA GGCCCTAACCCTGAGCTGA 
Cyba NM_007806.3 CCTCCACTTCCTGTTGTCGG TCACTCGGCTTCTTTCGGAC 
Cybb NM_007807.4 GGGAACTGGGCTGTGAATGA CAGTGCTGACCCAAGGAGTT 
Tyrobp NM_011662.2 ATGGGGGCTCTGGAGCCCT TCATCTGTAATATTGCCTCTGTGT 
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Gene Accession No. Forward Primer (5‘→3‘) Reverse Primer (5‘→3‘) 
Fcer1g NM_010185.4 CTGTCTACACGGGCCTGAAC AAAGAATGCAGCCAAGCACG 
Aif1 NM_019467.2 GAAGCGAATGCTGGAGAAAC AAGATGGCAGATCTCTTGCC 
Il1b NM_008361.3 CTTCCTTGTGCAAGTGTCTG CAGGTCATTCTCATCACTGTC 
Nos2 NM_010927.3 AAGCCCCGCTACTACTCCAT GCTTCAGGTTCCTGATCCAA 
Itgam NM_001082960.1  CATCAAGGGCAGCCAGATTG GAGGCAAGGGACACACTGAC 
Tnfa NM_013693.2 TGATCCGCGACGTGGAA ACCGCCTGGAGTTCTGGAA 
Gapdh NM_008084.2 AACTTTGGCATTGTGGAAGG GGATGCAGGGATGATGTTCT 
 
For amplifications (Table 2.12), a Mastercycler epgradient S® was used and the results were 
evaluated with the manufacturer’s software. Amplification specificity was confirmed by melting 
curve analysis and the quantification was carried out using the ΔΔCt method. 
Table 2.12 sqRT-PCR Program 
Step Temperature Time Cycles 
1. Initial denaturation 95°C 10 min  
2. Denaturation 95°c 15 s  
40x 3. Annealing 60°C 30s 
4. Elongation 72°C 30s 
5. Inactivation 95°C 10 min  
6. Melting curve 60°C – 95°C 20 min  
7. Final  95°C 15 s  
8. Store 4°C ∞  
 
2.3.2 Bacterial cloning 
2.3.2.1 Bacterial cultures 
 
For starting new bacteria cultures (Table 2.13), inoculums or aliquots were taken from -80°C 
long storage cryovials into 3-5 mL LB medium (for small scale culture) or 200-250 mL LB 
medium (for large scale cutures) containing appropriate selection antibiotic, placed in 37°C 
shaking incubators (200-250 rpm) and grown until required bacterial density was reached 
(usually overnight or 16 h).  
For long term storage, bacteria containing LB media was mixed with glycerol in a 1:1 ratio (v/v), 
placed in cryotubes and stored at -80°C. 
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Table 2.13 Bactria strains 
 
2.3.2.2 Plasmid isolation 
 
Bacterial plasmids were isolated from bacterial small cultures (3-5 mL) grown for 8h or 
overnight, using the QIAprep Spin Miniprep Kit or from big bacterial cultures (200-250 mL) 
using the PureLink® HiPure Plasmid Filter Maxiprep Kit. DNA concentration was measured using 
a Nanodrop spectrophotometer.  
 
2.3.2.3 Plasmid Digestion and Ligation 
 
The pSeq Tag Hygro B plasmids containing the full length or truncated Tyrobp were kindly 
provided by the group of Prof.Dr. Jochen Walter (Department of Neurology, University of Bonn, 
Germany). 
Plasmids (1 mg) were digested using EcoRI and BamHI restriction enzymes in appropriate buffer 
for 1.5 h, at 37°C (Table 2.14). The resulted bands were visualized by gel electrophoresis (1% 
agarose), using GelStar® Nucleic Stain on a Dark Reader Transilluminator, in the presence of 
100bp ladder. The correct bands were excised and purified via QIAquick Gel Extraction Kit, 
followed by MiniElute PCR Purification Kit for improved purity.  
Table 2.14 Digestion and Ligation Mixes  
Mix type Component Quantity Manufacturer Registered office 
Digestion Mix 
 H2O Up to 20 µL   
 Buffer A 2 µL Roche Grenzach-Wyhlen, DE 
 DNA 1 mg   
 EcoRI 1 µL (10 U) Roche Grenzach-Wyhlen, DE 
 BamHI 1 µL (10 U) Roche Grenzach-Wyhlen, DE 
Ligation Mix 
 DNA fragments Max 100 ng   
 H2O Up to 20 µL   
 Buffer 5x 4 µL Roche Grenzach-Wyhlen, DE 
 T4 ligase 1 µL (5U)  Roche Grenzach-Wyhlen, DE 
 
Competent bacteria strain Selection Manufacturer Registered Office 
Top10 Ampicillin Invitrogen, LifeTechnolgies GmbH Darmstadt, DE 
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Ligation of the purified DNA fragments into modified pLenti plasmids (kindly provided by the 
group of Prof. Brüstle, Institute of Reconstructive Neurobiology, University of Bonn, Germany) 
was performed using T4 ligase, overnight at 16°C (Table 2.14). The cloning strategy can be seen 
in Fig. 2.2. 
 
Figure 2.2 – Cloning strategy for obtaining the full length or truncated Dap12/Tyrobp 
overexpressing plasmids. The full length or truncated Tyrobp gene sequences were integrated 
between the EcoRI and BamHI restriction sites of the pLenti expression plasmid. Tyrobp had the 
-leading sequence followed by Flag-tag sequence. A HA-tag 
sequence was introduced after the Tyrobp sequence. The resulting plasmid expresses Tyrobp under 
an Elongation Factor 1α (EF1α) promoter and the transduced cells will present GFP signal. 
 
2.3.2.4 Bacterial Transformation and Ligation Confirmation 
 
Competent bacteria were transformed using 10 µL of the ligation mix (see 2.3.2.3), via the heat-
shock method (Table 2.15), then plated on agar containing proper selecting antibiotic 
(ampicillin 100 µg/mL)  and incubated overnight at 37°C.  
Table 2.15 Bacteria Transformation 
Step Quantity Temperature Time 
1. Bacteria thawing 100 µL aliquot on ice 20 min 
2. Incubation ligation mix with bacteria + 10 µL on ice 30 min 
3. Heat shock  42°C (water bath) 45 s 
4. Bacterial wall restabilisation  on ice > 1 min 
5. Liquid preculturing + 900 µL 37°C (shaker 300rpm) 1 h 
6. Bacteria harvesting – centrifugation 7000xg, 3 min 
7. Plating on agar 
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Inoculums of resulted colonies were grown in small culture volumes and verified by restriction 
enzyme digestion and/or sequencing of the isolated plasmids. The general structure of the 
resulted plasmids can be seen in Fig 2.3 and Table 2.16. 
Table 2.16 Cloned Plasmids 
Name Backbone Bacterial Selection Marker 
pLenti GFP pLenti Ampicilline 
pLenti TYROBP full length pLenti GFP Ampicilline 
pLenti TYROBP truncated pLenti GFP Ampicilline 
 
 
Figure 2.3 – General plasmid map of the vectors resulted after ligation of the inserts into the 
backbone plasmid. The ‘Gene of interest’ has been inserted between the EcoRI and BamHI 
restriction sites. The plasmid contains an ampicilline resistance gene for bacterial selection and an 
IRES-eGFP reporter sequence and blasticidine resistance gene for eukaryotic cell selection (scheme 
generated by PlasMapper 2.0). 
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2.3.3 Lentivirus Generation and Transduction of Cells  
 
For the overexpression of mutant proteins, lentiviral particles were generated. In this regard, 
the lentiviral plasmid containing the fragments of interest were mixed together with packaging 
plasmids from the ViraPowerTM Lentiviral Packaging Mix (Table 2.17) and added on HEK293FT 
cells pre-seeded on poly-L-lysine, in 15cm2 dishes (6.5 x106 cells/dish seeded in MEF media 24h 
before starting the virus generation protocol), as presented in Table 2.17.  
Table 2.17 Packaging Vectors 
Name Backbone Selection Marker Manufacturer Registered Office 
pLP1 pLP Ampicilline Invitrogen, LifeTechnolgies GmbH Darmstadt, DE 
pLP2 pLP Ampicilline Invitrogen, LifeTechnolgies GmbH Darmstadt, DE 
pLP3 pLP/VSVG Ampicilline Invitrogen, LifeTechnolgies GmbH Darmstadt, DE 
 
The virus was harvested 48h after the beginning of the production, filtered, aliquoted and 
stored frozen or used directly on ESdM cells for transduction. For this, ESdM cells were seeded 
in 6 well plates and transduced when they were cca. 60% confluent. After 48h, the medium was 
changed to fresh N2 medium. All the security level 2 (S2) experiments were conducted in 
accordance with local S2 material handling procedures.  
 
Table 2.18 Lentivirus generation (quantities per 15 cm2 dish) 
Step Component Amount 
1. Plasmid Mix Plasmid of interest 25 µg 
 pLP1 (pMDL gag/pol RRE) 25 µg 
 pLP2 (pRSV-Rev) 12.5 µg 
 pLP3  15 µg 
 H2O Up to 1.125 mL 
 CaCl2 (mM) 125 µL 
 HBSS 2x 1.25 mL 
2. Incubation 20 min, room temperature 
3. Adding drop-wise on new MEF media  
4. Refresh medium after 24h 
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2.3.3.1 Fluorescence-Activated Cell Sorting (FACS) Isolation of Transduced Cells 
 
The positively transduced cells were selected via fluorescence-activated cell sorting (FACS) 
based on their GFP expression signal. For this, cells were detached from the dishes, washed and 
kept in PBS until sorting. After sorting, the cells were collected in N2 media, centrifuged again 
and plated for expansion. The successfully tranduced cells were considered new cell lines and 
handled accordingly (for details see 2.2.2). The obtained cells are presented in Table 2.19. 
Table 2.19 Transduced Cell Lines 
Name Vector inserted Original cell line Selection Marker 
ESdM DAP12 Full Length pLenti TYROBP Full ESdM eGFP signal 
ESdM DAP12 Truncated pLenti TYROBP Truncated ESdM eGFP signal 
ESdM GFP pLenti GFP ESdM eGFP signal 
 
2.3.4 cDNA Microarray 
 
To determine changes in gene expression in mice following LPS treatments, microarray analysis 
of total brain RNA was performed. For this, three months old BL6 mice were i.p. treated with 
LPS (single or repeated) and analyzed on day 5 (Fig. 2.1). Lysis of whole brain was performed by 
mechanical homogenization using a TissueLyzer, in the presence of QIAzol reagent. Extraction 
of RNA was done accordingly to the QIAzol manufacturer recomandations, with -20°C 
incubation overnight for small RNA precipitation.  
Total RNA integrity and purity verification as well as further arrays were performed by Dr. 
Sinkkonen (Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, 
Luxembourg). The RNA was reverse-transcribed into double-stranded complementary DNA 
(cDNA). Further, cDNA was processed and hybridized onto Affymetrix GeneChip® Mouse Gene 
1.0 ST Arrays according to the Ambion® WT Expression kit for Affymetrix® GeneChip® Whole 
Transcript Expression Array Protocol and GeneChip® Whole Transcript Terminal Labeling and 
Hybridization User Manual for use with the Ambion® Whole Transcript Expression kit. 
Microarrays were scanned and imported into Partek® Genomics SuiteTM 6.4 for preprocessing, 
quality control and detection of differentially expressed genes (DEG). Appropriate statistic 
methods were used. For Ingenuity pathway analysis (IPA) lists of significantly DE mRNAs 
between (single or repeated) LPS treatment versus (single or repeated) PBS treatment were 
uploaded in the IPA tool (Ingenuity® Systems).  
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2.3.5 RNA Sequencing  
 
For genome-wide gene expression assessment in full length Tyrobp over-expressing ESdM cells, 
truncated Tyrobp over-expressing ESdM cells and GFP expressing control ESdM cells, the total 
RNA was extracted via mechanical homogenization using a TissueLyzer, in the presence of 
QIAzol reagent. Extraction of RNA was done accordingly to the QIAzol manufacturer 
recomandations, with -20°C incubation overnight for small RNA precipitation.  
Further array analysis was performed by Dr. Chris Gaiteri (Sage Bionetworks, Seattle, USA). 
Total RNA was used for the preparation of the sequence library using RNA TruSeq Kit. After 
rRNA depletion, the remaining RNA was converted into double stranded cDNA and adenine 
base was added at the 3’ ends of polished cDNA. Illumina supplied specific adaptors were 
ligated to cDNA and size selected to get an average of 200 bp insert size using AmpPure beads. 
After 15 cycles PCR amplification and AmpPure beads based purification, the final sequence 
library was obtained. Read mapping was done using the TopHat RNA-seq aligner (Trapnell and 
Schatz, 2009).  
 
2.4. Immunochemistry 
2.4.1 Immunohistochemistry (IHC) 
  
For collecting and PFA-fixing of brains, the protocol mentioned in section 2.1.3 was used. 
Coronal plane (20 µm extent in the rostal-caudal plane) slicing was performed using a cryostat 
microtome. Consecutive slices of 20 or 30 µm thickness containing the substantia nigra area 
were collected on glass slides and stored at -20°C until stained. 
An IHC general protocol is given in Table 2.21, for a more detailed list of the antibodies used, 
see Table 2.22.  
Image acquisition was done using an inverted microscope with ApoTome AxioObserver Z1 or an 
Olympus IX81 inverted confocal microscope. The pictures were visualized and processed with 
the manufacturer’s software.  
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Table 2.21 IHC protocol  
Step Solution Components Time  Temperature 
1. Blocking Blocking 
solution 
10% bovine serum 
albumin (BSA) 
5% normal goat 
serum (nGS) 
0.2% Triton 100x 
1 h Room temperature 
2. Primary antibody 
incubation 
 1st antibody in 
blocking solution 
2 h 
(overnight) 
Room temperature 
(4°) 
3. PBS wash     
4. Secondary antibody 
incubation 
 2nd antibody in PBS 2 h Room temperature 
5. PBS washing     
6. Mounting Mowiol    
 
Table 2.22 Antibodies (IHC, ICC, IP, WB) 
Antibody  Type Host Specificity Working 
conc. 
Manufacturer  Registered 
office 
Tyrosine hydroxylase 
(TH) 
1st mouse  1 µg/mL Sigma-Aldrich München, DE 
Tyrosine hydroxylase 
(TH) 
1st rabbit  1 µg/mL Millipore Schwalbach, 
DE 
β-III-tubulin 1st mouse  1 µg/mL Sigma-Aldrich München, DE 
Neuronal nuclei 
(NeuN) 
1st rabbit  1 µg/mL Millipore Schwalbach, 
DE 
Ionized calcium-
binding adapter 
molecule (Iba1) 
1st  rabbit   0.5µg/mL Waco  
Spleen tyrosine kinase 
(Syk) 
1st rabbit  5 µg/mL Santa Cruz 
Biotechnology 
Heidelberg, 
DE 
Phospho-tyrosine 
antibody 4G10 
1st mouse  5 µg/mL Millipore Schwalbach, 
DE 
Biotinylated antibody  2nd goat rabbit  2 µg/mL Dianova Hamburg, DE 
Biotinylated antibody  2nd goat mouse 2 µg/mL Dianova Hamburg, DE 
Horseradish 
peroxidase (HRP)- 
conjugated 
streptavidin  
2nd   0.1µg/mL Millipore Schwalbach, 
DE 
Cy3-conjugated Ab 2nd  mouse 2 µg/mL Dianova Hamburg, DE 
Cy3-conjugated Ab 2nd  rabbit 2 µg/mL Dianova Hamburg, DE 
Cy5-conjugated 
streptavidin 
2nd   2 µg/mL Dianova Hamburg, DE 
Alexa 488-conjugated 2nd  rabbit 2 µg/mL Invitrogen, 
LifeTechnologies 
GmbH 
Darmstadt, 
DE 
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For neuronal quantification, slides were double-stained with antibodies directed against the 
dopaminergic neuronal marker tyrosine hydroxylase (TH, 1 µg/mL) and with the neuronal nuclei 
marker (NeuN). TH positive immunostaining was used for the localization of substantia nigra 
pars compacta (SNpc; Baquet et al., 2009). For cell quantification, optical sections of four SNpc 
matched levels per mouse were used (McCormack et al., 2002). SNpc neurons were 
distinguished from the ones of ventral tegmental area based on size and orientation (Baquet et 
al., 2009). The TH positive neurons were only counted when the whole nucleus was contained 
within the section.  
For microglia evaluation, TH immunostaining was used for positioning in the slice, together with 
an antibody directed against the microglial marker Iba1. Microglial cells were counted in four 
matched levels containing substantia nigra pars reticulata (SNpr) pwe mouse.   
 
2.4.2 Immunocytochemistry (ICC) 
 
For cell culture immunostainings, cells were briefly washed with PBS and stained as mentioned 
in Table 2.23. For antibodies concentrations and product details, see Table 2.24. The stained 
material was stored at -20°C. 
Table 2.23 ICC Protocol 
Step Solution Components Time  Temperature 
1. Blocking Blocking solution 10% BSA 
5% nGS 
0.2% Triton 100x 
30 min Room 
temperature 
2. Primary antibody 
incubation 
 1st antibody in blocking 
solution 
1 h Room 
temperature 
3. PBS wash     
4. Secondary 
antibody 
incubation 
 2nd antibody in PBS 30 min Room 
temperature 
5. PBS washing     
6. Mounting Mowiol    
 
Image acquisition was done using an Olympus Confocal IX81 inverted confocal microscope. The 
pictures were visualized and processed with the manufacturer’s software.  
The positive stained cells were counted by using ImageJ software. For neuronal processes 
quantifications, the length of neurites was traced manually and quantified using the NeuronJ 
plug-in. 
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2.4.3 Immunoprecipitation (IP) 
 
For obtaining cell lysates, cells ware detached from the dish, washed in PBS and lysed by 
vortexing and incubation in 100 µL RIPA buffer, in the presence of EDTA, phosphatase and 
protease inhibitors (HaltTM Protease Inhibitor + EDTA kit), on ice. After 1h, the lysate was 
centrifuged (13,000xg) at 4°C and the supernatant was used for further determinations. 
For antigen precipitation, the lysate supernatant was incubated with magnetic Dynabeads® that 
were precoated with antibodies according to manufacturer’s specifications. The 
immunoprecipitation of the target antigen was performed as mentioned in Table 2.25. 
Table 2.25 Immunoprecipitation Protocol 
Step Solution Conditions Manufacturer Registered office 
1. Antigen (lysate) 
binding to beads 
100 µL sample 
 
1h, 4°C, 
rotation 
  
 + Dynabeads®  Invitrogen, 
LifeTechnologies  
Darmstadt, DE 
2. Magnetic separation 
of beads 
 Room 
temperature 
Invitrogen, 
LifeTechnolgies  
Darmstadt, DE 
3. Wash  200 µL  
washing buffer 
Room 
temperature 
Invitrogen, 
LifeTechnolgies  
Darmstadt, DE 
4. Elution & 
Denaturation 
20 µL  
elution buffer 
 
10 min, 70°C Invitrogen, 
LifeTechnolgies  
Darmstadt, DE 
10 µL 
 NuPage® LDS 
Sample Buffer 
 Invitrogen, 
LifeTechnolgies  
Darmstadt, DE 
1 µL  
β-mercapto-
ethanol 
 Carl Roth GmbH  Karlsruhe, DE 
5. Magnetic beads – antigen separation 
 
2.4.4 Western Blot (WB) 
The antigens isolated by immnoprecipitation (see 2.4.4) were loaded onto 10% NuPAGE® Bis-
Tris Gels and run in NuPAGE® MES SDS running buffer, under constant 130V. PageRuler Plus 
prestained protein ladder was used as marker. The protocol presented in Table 2.25 was used. 
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Table 2.25 Western Blot Protocol 
Step Solution Conditions 
1. Electrophoresis NuPAGE® MES SDS 130V 
2. Blot NuPAGE® transfer buffer 380 mA, 1 h, on ice 
3. Blocking PBST (PBS + 0.1% Tween) 
+ 5% blot-grade milk powder 
1 h, rotation 
4. Primary antibody 
incubation 
PBST  
+ 5% blot-grade milk powder 
Overnight, 4°C, rotation 
5. PBST washing  3x 15 minutes 
6. Secondary 
biotinylated antibody 
incubation 
PBST  
 
1 h, room temperature, rotation 
7. PBST washing  3x 15 minutes 
8. Peroxidase labeling PBST  
+ 5% blot-grade milk powder 
1 h, room temperature 
9. PBST washing  3x 15 minutes 
 
Detection was performed by using SuperSignal West Pico or SuperSignal West Femto kits and 
the pictures were visualized and 41cquired by a ChemiDoc Gel Imaging System. 
 
2.4.5 Enzyme-Linked Immunosorbent Assay (ELISA) 
 
For ELISA, mouse brains and plasma were collected as mentioned in section 2.1.3. After 
isolation, brains were homogenized in radioimmunoprecipitation assay buffer (RIPA buffer) 
containing proteases and HaltTM phosphatases inhibitor cocktails. After incubation on ice for 15 
minutes, the homogenates were centrifuged (13,000xg) and brain supernatants were collected. 
Tnfα and Il1β protein expression levels in the plasma or brain were quantified by using 
corresponding mouse Quantikine ELISA Kits, according to the manufacturer’s instructions. 
 
2.6 Other General Materials 
2.6.1 Technical Equipment 
Equipment Article Manufacturer Registered Office 
Autoclave Systec D150 Systec GmbH Wettenberg, DE 
Automatic pipettes 1, 10, 100, 1000 µL Eppendorf AG Hamburg, DE 
Centrifuge Megafuge 1.0R Heraeus Holding GmbH Buckinghamshare, UK 
Centrifuge  MCF 2360 LMS Tokyo, JP 
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Equipment (continued) Article Manufacturer Registered Office 
Electrophoresis  Power Supply EPS 301 Amersham Biosciences Buckinghamshare, UK 
Electrophoresis  40-0911 Paqlab Biotechnologies  Erlangen, DE 
FACS Sorter BD FACSDiva BD Biosciences Franklin Lakes, USA 
Flow Cytometer BD FACSCalibur BD Biosciences Franklin Lakes, USA 
Freezer (-20°C) Premium  Liebherr Biberach, DE 
Freezer (-20°C) Profiline GG5260 Liebherr Biberach, DE 
Freezer (-80°C) Herafreeze Heraeus Holding GmbH Buckinghamshare, UK 
Fridge (4°C) Medline LKUv 1612 Liebherr Biberach, DE 
Gel Imaging System ChemiDoc Bio-rad Munich, DE 
Homogenizer TissueLyserLT Qiagen Hilden, DE 
Incubator Hera cell 150 Heraeus Holding GmbH Buckinghamshare, UK 
Incubator Shaker innova 4300 New Brunswich 
Scientific 
Nürtingen, DE 
Incubator Shaker  Innova 44 New Brunswich 
Scientific 
Nürtingen, DE 
Laminar flow hood Hera safe Kendo Laboratory 
Producs GmbH 
Langenselbold, DE  
Microscope  Confocal Olympus IX81 Olympus Hamburg, DE 
Microscope  Axoskop 2 plus Carl Zeiss AG Oberkochen, DE 
Microscope Axiovert 40 CFL Carl Zeiss AG Oberkochen, DE 
Microscope  ApoTome AxioObserver 
Z1 
Carl Zeiss AG Oberkochen, DE 
Microtome Cryostat HM 560 M 
Cryo-star 
Thermo Fisher Scientific Waltham, USA 
Microwave Oven Severin 800 SEVERIN Elektrogeräte  Sundern, DE 
N2 Tank MVE 611 German-cryo Jüchen, DE 
Peristaltic Pump Pump drive PD 5001 Heidolph Schwabach, DE 
pH-meter CG840 Schott Mainz, DE 
Pipetteboy Cell Mate II Thermo Fisher Scientific 
Inc. 
Waltham, USA 
Scale Acculab Sartorius Göttingen, DE 
Shaker  KS-15 control Edmund Buhler GmbH Hechinge, DE 
Spectrophotometer NanoDrop 1000 ThermoScientific Waltham, USA 
Thermocycler T3  Biometra Göttingen, DE 
Thermocycler Mastercycler 
epgradient S 
Eppendorf Hamburg, DE 
Thermoshaker Thermomixer compact Eppendorf AG Hamburg, DE 
Transilluminator DarkReader DR89X Clare Chemical 
Research 
Dolores, USA 
Tube rotor VWR Tube Rotor VWR Langenfeld, DE 
Ultracentrifuge Sorvall Discovery 90 SE HITACHI Cambridge, UK 
Ultracentrifuge Sorvall RC 6+ ThermoScientific Waltham, USA 
Ultracentrifuge Sorvall 5B Plus Thermoscientific Waltham, USA 
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Equipment (continued) Article Manufacturer Registered Office 
Vacuum controller VacuuHandControl Vacuumbrand  Wertheim, DE 
Vacuum pump Vacuu-lan® network for 
lab 
Vacuumbrand Wertheim, DE 
Vortex 2X2 Velp Scientifica Usmate, IT 
Waterbath WB/OB7-45 Memmert GmbH & 
CoKG 
Schwabach, DE 
2.6.2 Consumables  
Product Specifications Manufacturer Registered Office 
Cell culture pipette 5, 10, 25 mL Sarstedt Nümbrecht, DE 
Cell scraper 17 mm Sarstedt Nümbrecht, DE 
Cell strainer 40 µm BD Biosciences Heidelberg, DE 
Chamber slides Lab-Tek™ 4 chambers Nalge Nunc Wiesbaden, DE 
Cryomolds 10 mm x 10 mm x 5mm Sakura Finetek Staufen, DE 
Culture dish  35, 100, 150 mm Sarstedt Nümbrecht, DE 
Culture dish 6-wells-plate Greiner Bio One Frickenhausen, DE 
Culture flask  75 cm2 Sarstedt Nümbrecht, DE 
Erlenmeyer flask 250 mL Schott-Duran Maintz, DE 
Filter  0.22 µm Sarstedt Nümbrecht, DE 
Filter  0.45 µm Corning Inc. Kaiserslautern, DE 
Filter  0.45 µm; steriflip Millipore Schwalbach, DE 
Filter Bottle top 500mL Millipore Schwalbach, DE 
Glass bottle 100, 500, 1000 mL Schott-Duran Maintz, DE 
Gloves Micro-touch ® Ansell München, DE 
IHC Glass cover slips 24x60 mm Engelbrecht Edermunde, DE 
IHC Glass slides Superfrost Plus ThermosScientific Rockford, USA 
Labels Tough-Spots ® 3/8’’ DiversifiedBiotech Dedham,USA 
Needels perfusion Venofix ® 23G Braun Melsungen, DE 
Needles injection 26 G BD Biosciences Heidelberg, DE 
Neubauer counting-
chamber 
0.100 mm Paul Marienfeld 
GmbH & Co. KG 
Lauda-Königshofen, 
DE 
Parafilm ® M Sigma-Aldrich München, DE 
Pasteur pipettes glass Brand Wertheim, DE 
Pasteur pipettes plastic Ratiolab Dreieich, DE 
Pipette tips  10, 100, 200 µL Starlab GmbH Hamburg,DE 
QPCR Optical 
Adhesive Film 
QPCR Seal  Paqlab 
Biotechnologies  
Erlangen, DE 
QPCR Plate Semi-Skirted 96 wells Paqlab 
Biotechnologies  
Erlangen, DE 
Scalpel Feather disposable scalpel 
No.10 
Thermo Fisher 
Scientific 
Waltham, USA 
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Product (continued) Specifications Manufacturer Registered Office 
Syringe  1, 50 mL BD Biosciences Heidelberg, DE 
Tubes 0.2 mL; 8-strip Biozym Scientific 
GmbH 
Hessich-Oldendorf, 
DE 
Tubes 0.5, 1.5, 2 mL Biozym Scientific 
GmbH 
Hessich-Oldendorf, 
DE 
Tubes 1.8 mL cryotubes Nalge Nunc Wiesbaden, DE 
Tubes 5 mL (flow cytometry) Sarstedt Nümbrecht, DE 
Tubes 15, 30 mL Sarstedt Nümbrecht, DE 
Tubes 13 mL (for bacteria) BD Biosciences Heidelberg, DE 
2.6.3 Chemicals and Reagents 
Product Manufacturer Registered Office 
Avertin Sigma-Aldrich München, DE 
4’,6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich München, DE 
Agarose Biozym Scientific GmbH Hessich-Oldendorf, 
DE 
Amyloid-β 1-42 (A β) Bachem Weil am Rhein, DE 
Bovine serum albumin (BSA) Sigma-Aldrich München, DE 
Desoxynucleotide triphosphates (dNTPs) 10mM Paqlab Biotechnologies  Erlangen, DE 
Ditiothreiton DTT 10mM Invitrogen, LifeTechnolgies 
GmbH 
Darmstadt, DE 
DNA ladder 100bp or 1kb Roche Grenzach-Wyhlen, 
DE 
Ethanol  99% Carl Roth GmbH  Karlsruhe, DE 
Ethidium bromide Carl Roth GmbH  Karlsruhe, DE 
Ethylendiamintetraacetic acid (EDTA) Carl Roth GmbH  Karlsruhe, DE 
Fluorescent beads – Fluoresbrite Polychromatic 
Red  Microspheres 1.0 μm 
Polysciences, Inc. Eppelheim, DE 
GelStar® Nucleic Stain Lonza Cologne GmbH Cologne, DE 
Glycerol 99% Sigma-Aldrich München, DE 
Heparine Ratiopharm Ulm, DE 
Hexanucleotide mix 10x Roche Grenzach-Wyhlen, 
DE 
Iso-propanol 99% Sigma-Aldrich München, DE 
Lipopolysaccharides (LPS) 1 mg/mL Enzo Life Sciences GmbH Lörrach, DE 
Media Opti-MEM Gibco, LifeTechnolgies 
GmbH 
Darmstadt, DE 
Methanol Carl Roth GmbH  Karlsruhe, DE 
Milk powder Carl Roth GmbH  Karlsruhe, DE 
Mounting reagent Mowiol 4-88 Sigma-Aldrich München, DE 
Normal goat serum Sigma-Aldrich München, DE 
NuPage® LDS Sample Buffer Invitrogen, LifeTechnolgies  Darmstadt, DE 
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Product (continued) Manufacturer Registered Office 
NuPAGE® Bis-Tris Gels 10% Invitrogen, LifeTechnolgies 
GmbH 
Darmstadt, DE 
NuPAGE® MES SDS Invitrogen, LifeTechnolgies  Darmstadt, DE 
NuPAGE® transfer buffer Invitrogen, LifeTechnolgies 
GmbH 
Darmstadt, DE 
PageRuler Plus Thermo Fisher Scientific Waltham, USA 
Paraformaldehyde (PFA) Merk & Co., Inc. Darmstadt, DE 
Phosphate buffer saline (PBS) Gibco, LifeTechnolgies 
GmbH 
Darmstadt, DE 
Poly-L-lysine Sigma-Aldrich München, DE 
QIAzol ® Qiagen Hilden, DE 
RIPA (RadioImmunoPrecipitation Assay) buffer  Sigma-Aldrich München, DE 
Sodium azide Sigma-Aldrich München, DE 
Tissue-Tek ® Embedding Reagent Sakura Finetek Staufen, DE 
Tris Carl Roth GmbH  Karlsruhe, DE 
TritonX100 Sigma-Aldrich München, DE 
Trypan blue 0.4% Gibco, LifeTechnolgies 
GmbH 
Darmstadt, DE 
Trypsin 0.25% Gibco, LifeTechnolgies 
GmbH 
Darmstadt, DE 
Tween Sigma-Aldrich München, DE 
β-mercaptoethanol 99% Carl Roth GmbH  Karlsruhe, DE 
 
2.6.4 Kits 
Product Manufacturer Registered Office 
Dynabeads® Protein A or G Invitrogen, LifeTechnolgies 
GmbH 
Darmstadt, DE 
HaltTM Protease Inhibitor Cocktail Thermo Fisher Scientific Waltham, USA 
MinElute PCR Purification Kit Qiagen Hilden, DE 
PureLink® HiPure Plasmid Filter Maxiprep Kit Invitrogen, LifeTechnolgies 
GmbH 
Darmstadt, DE 
QIAprep Spin MiniPrep Kit Qiagen Hilden, DE 
QIAquick Gel Extraction Kit Qiagen Hilden, DE 
Quantikine® Mouse TNFα Immunoassay R&D Systems Inc.  
Quantikine® Mouse IL1β Immunoassay R&D Systems Inc.  
REDExtract-N-AmpTM Tissue PCR Kit Sigma-Aldrich München, DE 
Rneasy® Lipid Tissue Kit Qiagen Hilden, DE 
Rneasy® Mini Kit Qiagen Hilden, DE 
SuperSignal West Femto Thermo Fisher Scientific Waltham, USA 
SuperSignal West Pico Thermo Fisher Scientific Waltham, USA 
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2.7 Softwares and Databases 
 
Name Manufacturer Registered Office 
GraphPrism GraphPad Software, Inc. San Diego, USA 
ImageJ National Institute of Health Mayland, USA 
IPA Ingenuity ® Systems Redwood, USA 
KEGG Pathways Database http://www.genome.jp/kegg/pathway.html 
PlasMapper 2.0 http://wishart.biology.ualberta.ca/PlasMapper/index.html 
 
2.8 Statistical Analysis 
 
Data presented as mean ± SEM (standard error measurements) of at least three independent 
experiments. Data analyzed by students t-test or one-way ANOVA followed by Bonferroni post-
hoc test comparing all columns using GraphPrism computer software (GraphPad Software, 
USA). Results are considered significant if *p < 0.05, **p < 0.01, ***p < 0.001. 
Results 
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3. Results 
3.1 TREM2 Deficient Mouse Characterization 
3.1.1 Aged TREM2 Deficient Mice Show Increased Levels of Inflammatory Transcripts 
 
It was reported previously that the absence of TREM2 in vitro (Takahashi et al., 2005) and in 
vivo (Piccio et al., 2007; Takahashi et al., 2007), as well as in Nasu-Hakola disease (Bianchin et 
al., 2010; Kaneko et al., 2010b; Satoh et al., 2011b) leads to different microglial cytokine 
release. Thus, in the present study, the cytokine profile of the TREM2 KO mouse model was 
investigated in whole mouse brain by sqRT-PCR (Fig. 3.1).  
 
Figure 3.1 – Increase of microglia- and astrocytes-related mRNA levels in aged TREM2 knock-out 
(KO) mice. Transcripts of microglial Allograft inflammatory factor 1 (Aif1), Tumor necrosis factor 
alpha (Tnfa), Interleukin 1 beta (Il1b) or astroglia specific marker Glial fibrillary acidic protein (Gfap) 
were measured in TREM2 KO or wild type (WT) control mice of 3, 6, 12 or 24 months of age. 
Differences in the transcript levels were observed only in 24 months old TREM2 KO mice. n ≥ 3 
animals. 
Mice screened at 3, 6 or 12 months presented similar levels of microglia activation markers 
Aif1, Tnfa, Il1b mRNA levels (Fig. 3.1). At 24 months, TREM2 KO animals presented higher levels 
of Aif1 and Il1b compared with TREM2 WT controls (Fig. 3.1). Due to the presence of astrogiosis 
in brains affected by Nasu-Hakola disease (Satoh et al., 2011b), astroglia specific marker Gfap 
mRNA was also assayed in TREM2 KO mice of different ages. At 24 months, TREM2 KO animals 
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presented higher levels of Gfap compared with TREM2 WT controls, but without reaching 
significance (Fig. 3.1). 
 
3.1.2 Changed Microglial Morphology in Adult TREM2 KO Mice  
 
A feature of microglial cells is their ability to respond to stimuli by changing their cellular shape 
and processes (Ransohoff and Perry, 2009). To investigate possible dysfunctions in the response 
of TREM2 deficient microglia to inflammatory stimulation, additional groups of mice were 
challenged with LPS or PBS accordingly to a repeated LPS challenge paradingm described by 
Cardona and colleagues (4 daily doseses of 1 μg LPS per gram body weight, gbw LPS; Cardona et 
al., 2006; Fig. 2.1).  Brain slices of 3 months-old TREM2 KO and WT controls were stainind 
against the microglial marker Iba1 and different morphological parameters were used to 
measure the microglial changes in TREM2 KO and WT mice (Fig. 3.2).  
 
 
Figure 3.2 – Changed microglial morphology in TREM2 KO animals. a – Representative images of 
microglial marker Iba1 immunostaining showing genotype- and treatment-related morphological 
differences. Scale bar: 25 µm; b - Total area covered by microglia soma or (c) soma plus processes 
presents decreased area coverage in TREM2 KO mice, further accentuated by LPS treatments; d - 
Iba1 soma intensity measurement presents a significant increase in the TREM2 KO animals treated 
with LPS compared with the other experimental groups. a.u. – arbitrary units; n=4. 
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The TREM2 KO animals showed significantly reduced microglial cell bodies area compared with 
TREM2 WT animals in the absence of LPS treatment (155.9 ± 7.68 pixels2 in TREM2 KO mice vs. 
262.3 ± 13.59 pixels2 in TREM2 WT,  p < 0.001; Fig. 3.2b). LPS treatment decreased further the 
microglial soma area in TREM2 KO animals (from 155.9 ± 7.68 pixels2 in PBS treated mice to 
127.5 ± 4.67 pixels2 in TREM2 KO animals treted with LPS, p < 0.001; Fig. 3.2b). After LPS 
treatment, TREM2 WT animals showed decreased microglial soma area compared with PBS 
treated mice (from 262.3 ± 13.59 pixels2 in PBS group to 174.7 ± 5.41 pixels2 in LPS treated 
TREM2 WT mice, p <0.001; Fig. 3.2b).   
The total area covered by microglia (soma and processes) presents a similar pattern with the 
soma area in TREM2 WT and KO animals treated with PBS or LPS (Fig. 3.2b). However, only the 
TREM2 KO animals treated with LPS were statistically significantly different compared to PBS 
treated TREM2 WT animals (from 5507 ± 759 pixels2 in PBS treated TREM2 WT mice, to 2094 ± 
234 pixels2 in LPS treated TREM2 KO animals, p < 0.001; Fig. 3.2c). 
The intensity of the Iba1 staining was measured as additional readout of microglial activation, 
showing similar levels between TREM2 WT and KO animals when treated with PBS, and 
significantly higher levels in the TREM2 KO animals after the repeated LPS treatment compared 
with the WT animals (from 5.02 ± 0.72 fluorescence units in TREM2 WT treated with LPS to 8.37 
± 0.94 fluorescence units in TREM2 KO treated with LPS, p < 0.01; Fig. 3.2d).  
 
3.1.3 Similar Inflammatory Transcripts in TREM2 KO and WT mice after Systemic LPS 
Challenges  
 
To investigate possible changes in gene expression triggered by LPS challenges, the mRNA levels 
of microglial marker gene Aif1 and proinflammatory genes Il1b or Tnfa were investigated in 
TREM2 KO mice and WT controls. The transcriptsm showed similar response to LPS application 
in both TREM2 KO and WT animals (Fig. 3.2).  
 
Figure 3.3 – TREM2 deficiency is not affecting the normal proinflammatory response inside CNS. 
Mice were treated with LPS intraperitoneally. n ≥ 3.  
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3.2 Immune System Involvement in Dopaminergic Degeneration Induced by Systemic 
LPS Challenges 
 
Cardona and colleagues briefly described a fast protocol of neuroinflammation triggered by 
repeated i.p. LPS challenges of mice (Cardona et al., 2006). To obtain insights on the 
mechanisms involved in this process, the repeated LPS treatment protocol was in BL6 mice and 
compared with a single cumulative dose of i.p. LPS (Fig. 2.1).  
 
3.2.1 Microglial Activation by Systemic LPS Treatments 
 
The effect of single or repeated LPS challenge on microglia of BL6 mice was investigated at two 
different time points: on experimental day 5 and 19 (Fig. 2.1). A sqRT-PCR analysis of the 
microglial marker Aif1 mRNA in the whole mouse brain lysate revealed that on day 5 after 
single LPS treatment, a slight increase in the mRNA level was detectable, whereas after the 
repeated LPS treatment was registered a significant increase compared with the single LPS 
treatment (from 1.66 ± 0.28 FC in single LPS treated group to 3.08 ± 0.18 FC in repeated LPS 
group, p<0.01; Fig. 3.4). Nineteen days after the start of the treatment, the mRNA level of Aif1 
gene has returned to normal control values (Fig. 3.4).  
 
 
Figure 3.4 – Aif1 mRNA levels in whole mouse brain are significantly increased on day 5 after 
repeated LPS treatment (left) and returned to control values on day 19 (right). On day 5 after LPS 
treatment, sqRT-PCR measurements of Aif1 mRNA show increased levels that were significant after 
repeated LPS application. The Aif1 transcript levels returned to control levels on day 19. n ≥ 3. 
 
Next, the levels of the Aif1 expression product, the Ionized calcium-binding adapter molecule 1 
(Iba1), were investigated in mice after i.p. application of LPS. In this regard, substantia nigra 
pars reticulata (SNpr), a brain region that presents a relative high amount of microglial cells 
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compared with other brain regions (Kim et al., 2000; Lawson et al., 1990), was 
immunohistochemically (IHC) analyzed in mice systemically challenged with LPS accordingly to 
the single or repeated treatment paradigms (Fig. 3.5a). On day 5, IHC analysis showed an 
increase of Iba1 immunoreactivity after a single LPS challenge (from 32.53 ± 2.11 cells per 
section in PBS controls to 145.3 ± 8.35 cells per section in LPS challenged mice, p<0.001; Fig. 
3.9b). However, after repeated LPS aplication, mice showed on day 5 a lesser extent of Iba1 
staining after repeated treatments (from 32.53 ± 2.11 cells per section in PBS controls to 77.07 
± 2.24 cells per section in LPS treated mice, p<0.001) (Fig.3.5b). On day 19, the 
immunoreactivity of Iba1 returned to the initial levels (Fig. 3.5b). 
 
Fig 3.5 - Immunoreactivity of the microglial marker Iba1 is significantly increased on day 5 after LPS 
treatments and returnes to control level on experimental day 19. a – Representative images of Iba1 
immunostaining (gren) in the substantia nigra pars compacta (SNpc) and pars reticulata (SNpr) 
presented. Dopaminergic marker tyrosine hydroxylase (TH, red) was used for defining the SNpc and 
SNpr anatomical areas. Scale bar: 50 µm, insert: 25 µm; b – Quantification of the Iba1 positive cells 
on day 5 after treatment (left) presents increased Iba1 immunoreactivity after LPS application, with 
the single LPS challenge exceeding significantly the levels reached by the repeated LPS treatment. On 
day 19, Iba1 immunoreactivity returned to control levels. n ≥ 3 animals.  
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3.2.2 Proinflammatory Transcripts  in Mice Systemically Challenged with LPS 
 
Activated microglia release a broad spectrum of pro- or anti-inflammatory molecules as 
response to changes in the brain parenchyma (reviewed in Neumann et al., 2008; Ransohoff 
and Perry, 2009). For this reason, a proinflammatory cytokines profile in whole brain of mice 
was carried out by sqRT-PCR on day 5 or 19 after systemical application of LPS accordingly to 
the single or repeated treatment paradigms (Fig. 3.6). For this, Tnfa, Il1b and Nos2 mRNA were 
chosen as markers of microglial activation. When assayed on day 5, mice i.p. challenged once 
with LPS showed a slight up-regulation of Tnfa and Il1b brain mRNA levels, but no modulation 
of Nos2 mRNA (Fig 3.6). However, the repeated LPS challenge of mice lead to a significant 
increase of Tnfa mRNA compared with PBS treated controls or even single treated mice (from 
3.26 ± 1.17 FC after single LPS challenge, to 8.88 ± 2.19 FC after repeated LPS application, 
p<0.05; Fig. 3.6a). The Il1b mRNA level was also significantly increased by the repeated 
treatmetnt (from 7.27 ± 1.46 FC after single LPS treatment, to 32.47 ± 12.5 FC after the 
repeated treatment; Fig. 3.6a). In contrast with the single LPS aplication, the Nos2 mRNA was 
induced by the repeated treatment (0.8 ± 0.08 FC after single LPS aplication, to 3.2 ± 0.4 FC 
after repeated LPS aplication, p<0.001; Fig 3.6a). 
 
Figure 3.6 – Transcription levels of proinflammatory markers Tnfa, Il1b and Nos2 in whole mouse 
brain were increased on day 5 after repeated LPS treatments, with values returning to control 
level on day 19. a – On day 5, Tnfa, Il1b and Nos2 mRNA levels were increased after LPS treatments, 
with the highest increase reached after repeated challenges; b – On experimental day 19, the 
transcripts levels were unchanged after single or repeated LPS challenge compared to the control, 
with the exception of Il1b which maintained an increased mRNA level after repeated LPS challenge. 
n.d.: not detected. n ≥ 3. 
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However, on day 19, only Il1b mRNA level after the repeated LPS treatment showed 
significant differences (from 1.33 ± 0.6 FC in single LPS treatment to 3.35 ± 1.3 FC after 
repeated LPS treatment, p<0.05; Fig 3.6b). The levels of Tnfa and Nos2 mRNA in whole mose 
brain lysates were similar in single or repeated LPS or PBS challenged animals (Fig. 3.6b). 
Since the method of LPS application is based on i.p. injections, the brain response to LPS was 
next compared with the peripheral response to LPS. In this regard, Enzyme-Linked 
Immunosorbent Assay (ELISA) was used to assay the protein levels of Tnfα and Il1β in brain 
and blood plasma of mice on day 5 after single or repeated LPS i.p. challenges (Fig. 3.11). 
Data show that the response to single or repeated peripheral LPS aplication leads to increase 
levels of Tnfα and Il1β cytokines productoin in the brain after both treatment paradigms. 
After the repeated LPS treatments, Tnfα and Il1β levels are significantly increased compared 
with the single LPS aplication: for Tnfα from 3.5 ± 1.4 pg/mL after single LPS application to 
44.4 ± 12.1 pg/mL after repeated LPS application (p<0.001) and for Il1β from 21.4 ± 4.8 
pg/mL (single LPS) to 84.2 ± 12.4 pg/mL (repeated LPS; p<0.05; Fig. 3.7a). In plasma however, 
both Tnfα and Il1β levels are increased after the LPS treatments, but to similar levels (Fig. 
3.7b). 
 
 
Figure 3.7 – Different proinflammatory cytokines response to LPS stimulation in the brain 
compared with the periphery when measured on experimental day 5. a - Enzyme-linked 
immunosorbent assay (ELISA) measurements of cytokines in brain shows pronounced elevation of 
Tnfα and Il1β cytokines after repeated treatment; b – Plasma levels of Tnfα and Il1β showed similar 
response to LPS after single or repeated treatment. n.d.: not detected. n = 3; data provided by Dr. 
Yiner Wang. 
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3.2.3 Loss of Dopaminergic Neuronal Triggered by Systemic LPS Challenges 
 
Dopaminergic neurons were previously demonstrated to be affected by LPS-triggered microglia 
activation (Arai et al., 2004; Hernández-Romero et al., 2012; Kim et al., 2000). Therefore, the 
dopaminergic system after single or repeated LPS administration in BL6 mice was explored 
next.  
 
 
Figure 3.8 – Repeated LPS challenge of mice lead to dopaminergic neuronal loss on day 19. a – 
Representative images of TH/NeuN immunostaining in the repeated LPS treatment group (bottom) 
compared with the repeated PBS treatment group (top). Scale bar: 150 µm, insert: 50µm; b – 
Quantification of TH and NeuN positive cells shows induced loss of TH and NeuN positive neurons after 
systemic repeated LPS application. n ≥ 3. 
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SN pars compacta (SNpc) region of the brain contains the highest accumulation of 
dopaminergic perykaria. Serial sections of SNpc were analyzed on day 19 after single or 
repeated LPS challenges of mice by immunostainng of the dopaminergic specific marker 
Tyrosine hydroxylase (TH) and Neuronal nuclei marker (NeuN). SNpc serial sections showed a 
relative reduction of the number of TH positive cell bodies (from an average of 134.6 ± 6.24 
cells per section, to 80.28 ± 6.20 cells per section, p < 0.001; Fig. 3.8b) and of NeuN positive 
cells (from 277.9 ± 14.30 cells per section to 178.4 ± 12.25 cells per section, p<0.001; Fig. 3.8c) 
after repeated LPS application. 
 
3.2.4 Brain Transcriptome Analysis of Systemic LPS Challenged Mice  
 
To identify key players in the dopamiergic degeneration triggered by the LPS treatments, a 
transcriptome analysis comparing the single LPS challenge and the repeated LPS treatment was 
performed next. 
Whole brain cDNA array of mice challenged with LPS was analysed. A number of 194 genes 
were found significantly changed after the single LPS treatment and 334 genes after the 
repeated treatment, compared with appropriate PBS controls (false discovery rate (FDR) < 0.05; 
absolute log2 fold change (FC) ≥ 0.5). Volcano plot representation proved that the diferentially 
expressed genes (DEG) were mostly up-regulated and that the repeated LPS treatment triggred 
a higher number of DEG compared with the single treatment (Fig. 3.9).   
 
Figure 3.9 – Volcano plots display of differentially expressed genes (DEG) in the brain reveal 
increased DEG levels in repeated LPS challenged mice on day 5. Each circle represents a gene. The 
genes corresponding to significant DEG (fold change (FC) ≥ 0.5, false discovery rate (FDR) < 0.05) 
depicted in red. Blue circles above the horizontal line represent genes with significant differences in 
expression between LPS and PBS but with weak fold changes. n = 6; data analysed in collaboration 
with Dr. Sinkkonen, University of Luxembourg. 
56 
 
Using more stringent transholding parameters (FDR < 0.01, FC ≥ 0.5), 91 DEGs were identified 
and represented within a heatmap (Fig. 3.10). Again, the repeated treatment revealed a 
completely different expression profile when compared with single LPS treatment or PBS 
controls, encompassing most of the highest number of up-regulated DEG. The single LPS 
treatment led to an up-regulation of genes when compared with PBS control, but to a lesser 
extent than in the case of the repeated LPS treatment group (Fig. 3.10). 
 
 
Figure 3.10 - Different gene expression pattern in mice treated repeatedly with LPS compared with 
mice treated once with a cumulative dose of LPS. Genes were selected on fold change log2 absolute 
values (unannotated genes were removed). Red blocks represent up-regulated and blue blocks 
represent down-regulated genes. n = 6 animals; data analysed in collaboration with Dr. Sinkkonen, 
University of Luxembourg. 
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An Ingenuity Pathway Analysis (IPA) for exploring the general significant biological functions 
related to the array data (FDR < 0.05) was performed. The top ten pathways are presented in 
Fig. 3.11. The IPA analysis revealed that many of the DEG up-regulated in the brain by LPS 
treatment were immune-related (e.g. enrichment of the immune cell trafficking pathway, 
inflammatory response pathway, inflammatory disease pathway). Other enriched pathways 
were represented by cellular movement, cellular function or maintenance pathways (Fig. 3.11). 
However, the biological functions analyzed by IPA generally proved a stronger enrichment by 
the repeated LPS treatment compared with the single LPS treatment.  
 
Figure 3.11 – Ingenuity Pathway Analysis of diferentially expressed genes (FDR < 0.05) in whole 
mouse brain on experimental day 5 after single or repeated LPS challenge. Top ten most enriched 
functions after single or repeated LPS treatment represented. Arrows are pointing to immune-
related pathways. n = 6 animals; data analysed in collaboration with Dr. Sinkkonen, University of 
Luxembourg. 
 
3.2.5 Phagosome- and Complement-related Pathways Enriched by Systemic LPS Challenges 
 
To get further insights on the difference between the single and the repeated LPS treatment 
mechanisms, a more detailed analysis of DEG was performed. In Fig. 3.12a, a Venn diagram 
summary of the number of genes selectively and significantly (FDR < 0.05; FC ≥ 2) up-regulated 
in the brain tissue on day 5 after single or repeated LPS treatment compared to the PBS is 
presented (for a comprehensive list of the genes, see Appendix).  
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Figure 3.12 – Higher number of DEGs and associated pathways in the repeated LPS treatment 
group compared with the single treatment group. a – Venn diagram depicting DEG (FDR < 0.05, FC ≥ 
2) distribution per treatment group. Only 3 DEG are specific to the single treatment, whereas 58 DEG 
are specific to the repeated treatment. A common single and repeated group of 22 DEG was 
observed. b - Kyoto Encyclopedia of Genes and Genomes (KEGG)-based pathway comparison of the 
80 genes up-regulated after the repeated LPS treatment and the 25 genes up-regulated by the single 
LPS treatment. The phagosome pathway ranked as the most selectively up-regulated pathway in the 
repeated LPS challenge, whereas complement and coagulation cascade was found to be enriched in 
the brains after both single and repeated treatments.  n = 6 animals; data analysed in collaboration 
with Dr. Sinkkonen, University of Luxembourg. 
Only 3 DEG are specifically up-regulated by the single treatment, of which which two are 
indirectly linked to immune function (Fig. 3.12a, Appendix). A number of 22 DEG are common 
to both single and repeated LPS treatments, most of them being immune-related genes, e.g. 
complement components, chemokines and major histocompatibility (MHC) molecules (Fig. 
3.12a, Appendix). A total number of 58 DEG were uniquely up-regulated by the repeated 
treatment, also mainly immune-related genes, e.g. complement components, Fc-receptors and 
MHC molecules (Fig. 3.12a, Appendix). Next, a Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway analysis of all the 80 (58 specific and 22 common) genes up-regulated after 
repeated LPS treatment in comparison to single dose treatment was performed (Fig. 3.12b). 
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The most prominantly up-regulated pathway emerging in the KEGG analysis after repeated LPS 
application was represented by the phagosome pathway (12 DEG after repeated challenge vs. 4 
DEG after single LPS challenge; Fig. 3.12b). Interestingly, the complement cascade was the 
strongest commonly erriched pathway by both single and repeated LPS challenge (7 DEG after 
the repeated LPS challenge vs. 6 DEG after the single LPS challenge; Fig. 3.12b). Among these 
pathways, elements specific to a certain type of infectious agents were found (e.g. to 
Staphylococcus aureus infection, Chagas disease or Herpes simplex infections), but they were 
inprobable in the experimental set-up used (Fig. 3.12b).  
 
Figure 3.13 – Specific and common DEG of the phagosome pathway enriched by the LPS 
treatments. Specific DEG of the endoplasmic reticulum-mediated phagocytosis after the repeated 
LPS challenges (shown within red framed pink boxes) were: major histocompatibility complex I 
members (here depicted as MHCI), complement cascade members (CR3 and its subunit αMβ2), 
targeted phagocytosis receptors (FcγR) and NADPH components (p22phox). Members of the same 
phagocytosis pathway common to both single and repeated LPS treatment groups (shown in black 
framed pink boxes) were represented by lysososmal proteases (cathepsin S), NADPH components 
(gp91) and complement cascade members (iC3b). No members of the endoplasmic reticulum-
mediated phagocytes were found up-regulated specifically after single LPS challenge. n=6; data 
analysed in collaboration with Dr. Sinkkonen, University of Luxembourg. 
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A more detailed KEGG analysis of the phagosome pathway in whole brain mRNA of mice 
systemically challenged with LPS and analyzed on experimental day 5, was performed to 
identify common and specific DEG contributing to the pathway (Fig. 3.13). In the KEGG analysis, 
elements common to both acute and repeated LPS challenge were represented by the 
complement cascade member C3, the lysosomal protease Cathepsin S (Ctss), and the gp91 
subunit (Cybb) of the nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) complex 
(Fig. 3.13 and Appendix). Elements unique to the repeated LPS challenges were composed of 
MHC class I members (H2-d1, H2-q6, H2-q7), complement cascade members (C3 and Integrin 
αMβ2, Itgam - part of the complement receptor 3, CR3), phagocytosis-related molecules (Fcer2b, 
Fcgr3, Fcgr4) or p22phox (Cyba), member of the NAPDH complex (Fig. 3.13 and Appendix).  
Next, a validating sqRT-PCR of representative elements of the array was performed (Fig. 3.14). 
The mRNA level of two common key adaptor molecules implicated in phagocytosis (DAP12 
encoded by the TYRO protein tyrosine binding protein - Tyrobp gene and the common γ chain 
encoded by Fcer1g gene), together with the mRNA level of two phagosome-related NADPH 
oxidase members (p22phox – Cyba and gp91 – Cybb) were chosen to be further investigated.  
 
Figure 3.14 - mRNA levels of elements involved in phagocytosis (Tyrobp, Fcer1g) or phagocytosis-
related oxidative stress (Cyba, Cybb) in whole mouse brain on day 5 after single or repeated LPS 
treatment. TYRO proteintyrosine kinase-binding protein (Tyrobp, encoding the DAP12 protein) mRNA 
was slightly increased by the repeated LPS treatment, whereas high-affinity IgE receptor γ 
polypeptide (Fcer1g, encoding the common Fcγ chain protein) was significantly increased by the 
repeated LPS challenges. NADPH oxidase components cytochrome b-245, α polypeptide (Cyba, 
encoding the p22phox protein) and cytochrome b-245, β polypeptide (Cybb, encoding gp91phox) 
mRNA levels were significantly up-regulated already by the single LPS treatment. After the repeated 
LPS challenges, the mRNA level of Fcer1g, Cyba and Cybb was further significantly increased. n = 6 
animals. 
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Whole brain mRNA of mice systemically challenged with LPS after the single or repeated 
treatment paradigms were analyzed on experimental day 5. Tyrobp and Fcer1g led to a similar 
pattern of up-regulation in the mRNA levels after both LPS treatment paradigms, with a higher 
increase after the repeated challenge. Fcer1g reached significance after the repeated 
treatement, from 1.91 ± 0.28 FC, after single LPS challenge, to  3.1 ± 0.19 FC after repeated LPS 
challenge, p<0.05; Fig 3.14. Both Cyba and Cybb mRNA levels were significantly increased by 
the single treatment and even significantly further increased by the repeated LPS challenge. 
Thus, Cyba gene transcription was increased from 2.91 ± 0.26 FC (single LPS) to 3.64 ± 0.24 FC 
(repeated LPS; p<0.01; Fig. 3.14) and Cybb from 4.33 ± 0.94 FC (single LPS) to 9.8 ± 0.83 FC 
(repeated LPS; p<0.001; Fig 3.14).   
 
3.2.6 C3 Deficiency Abrogates Dopaminergic Neuronal Loss after Repeated LPS Challenges 
 
To elucidate the mechanism of dopaminergic neuronal loss, the cDNA array data and related 
pathways analysis obtained on day 5 after single or repeated LPS treatment of mice (see 
sections 3.2.4-5) were analyzed thoroughly.  
Complement cascade was found highly represented in the brain within the common elements 
of the single and repeated LPS treated animals (Fig. 3.12b, 3.13, Appendix). Thus the 
complement pathway was analyzed in more detail (Fig. 3.15). The array data provided evidence 
on the enrichment of the first components of the classical/alternate pathway (C1q, SerpinG1, 
C4, C3, HF1), with C3 being a critical key element on day 5 after LPS challenge (Fig 3.15). 
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Figure 3.15 – DEG in the complement system pathway in mice after single or repeated treatments 
with LPS vs. PBS on experimental day 5. Ingenuity Pathway Analysis performed was on significantly 
DEG (FDR < 0.05) in each condition (single and repeated LPS treatment). The canonical complement 
pathway showed a significant enrichment in both conditions (p < 0.05). The overlay corresponds to 
repeated treatment and significant up-regulated genes are shown in red color. n = 6; data analysed 
in collaboration with Dr. Sinkkonen, University of Luxembourg.  
 
To confirm the array results, sqRT-PCR was performed. The sqRT-PCR analysis showed that C1q 
was not modulated by the LPS challenges (Fig 3.16). C3 and C4 responded to the single LPS 
application with a slight increase in the mRNA level, whereas Itgam levels remained unmodified 
compared with the PBS control (Fig. 3.16). However, the repeated LPS application led to a 
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significant increase in mRNA above the single challenge levels for C3 (from 5.58 ± 1.02 in the 
single LPS treated group, to 7.75 ± 0.82 FC in the repeated teated group, p < 0.001), C4 (from 
2.26 ± 0.45 – single LPS, to to 9.84 ± 2.60 FC – repeated LPS, p < 0.01) and Itgam (from 0.98 ± 
0.2 FC – single LPS, to 4.32 ± 0.14 FC, p < 0.001; Fig. 3.16).  
 
 
Figure 3.16 - Transcription levels of complement cascade members C3, C4 and Itgam in whole 
mouse brain on experimental day 5 are significantly increased after repeated LPS treatment. The 
classical pathway initiator C1q is irresponsive to the LPS challenge, whereas C3 and C4 transcripts of 
the alternate pathway are showing an up-regulation induced by repeated LPS treatment. Itgam (CR3) 
transcripts were up-regulated only by the repeated LPS treatment. n=6. 
 
C3 was identified as causal factor of dopaminergic degeneration triggered by repeated systemic 
LPS application, thus it was hypothesized that the absence of C3 should block the dopaminergic 
neuronal loss. For this C3 KO and WT controls were challenged using the repeated LPS 
treatment paradigm and analyzed on day 19 (Fig. 3.17).  
 
 
Fig 3.17 – C3 KO mice are resistant to dopaminergic neuronal loss after repeated LPS challenges 
compared with C3 WT controls. Quantification of TH and NeuN positive cells shows induced loss of TH 
and NeuN positive neurons after systemic repeated LPS application. n = 3 animals. 
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As expected, in C3 WT mice lower number of TH and NeuN positive neurons on experimental 
day 19 after the LPS treatment was registered, whereas C3 KO animals were unresponsive to 
the repeated LPS challenges (Fig. 3.17). In detail, the WT animals showed decreased neuronal 
numbers from 115.1 ± 6.86 cells per section after PBS treatment to 75.76 ± 7.27 cells per 
section after LPS treatment (p < 0.001, whereas the C3 KO mice presented 110.1 ± 8.63 cells per 
section after PBS treatment and 117.0 ± 6.22 cells per section after repeated LPS treatment 
(Fig. 3.17). 
 
3.3 DAP12/TYROBP Acts as Causal Regulator in Late Onset AD (LOAD) 
3.3.1 Microglial Cluster Enriched in Transcripts of LOAD Brains  
 
In collaboration with the groups of Dr. Chris Gaiteri (Sage Bionetworks, USA), Prof. Dr. Erick 
Schadt (Icahn Institute of Genomics and Multiscale Biology, USA) and Prof. Valur Emilsson 
(University of Iceland), a gene regulatory networks in 1647 post-mortem brain tissue samples 
from late onset Alzheimer’s disease (LOAD) patients and non-demented subjects was 
constructed via an integrative network-based approach. Within the LOAD network, DAP12 
(encoded by the TYROBP gene) was identified as key regulator enriched in an immune/ 
microglia-specific module (Zhang, Gaiteri,Bodea et al., 2013). 
DAP12/Tyrobp as key regulator in the brain immune module is further confirmed by its strategic 
position inside the microglial phagocytosis-related signaling pathway. A more detailed analysis 
of the immune/microglia module in the LOAD brains revealed that many of the phagocytosis 
pathway members are enriched, with DAP12/Tyrobp being the first member in the pathway 
(Fig. 3.23; Zhang, Gaiteri, Bodea et al., 2013). Among the enriched elements in the 
immune/microglia module in the LOAD brains, were found members of the phagocytosis-
related actin reorganization pathway (e.g. Lat, Vav, Rac), together with members of the 
phagocytosis-related oxidative burst (e.g. Ncf2, Ncf4, Cyba, Cybb; Fig. 3.23; Zhang, Gaiteri, 
Bodea et al., 2013). 
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Figure 3.18 – Phagocytosis pathway of the immune/microglia cluster in late onset Alzheimer’s 
disease (LOAD) gene-expression analysis. Members of the pathway found DE marked in red, TREM2 
and DAP12/Tyrobp position highlighted in green (analysis based on the data provided by Dr. Chris 
Gaiteri, Sage Bionetworks, Seattle, USA; published in Zhang, Gaiteri, Bodea et al., 2013). 
  
3.3.2 Features of LOAD Recapitulated by DAP12 Overexpressing Microglial Cells 
 
To verify the results obtained in the LOAD gene-expression analysis, full length mouse Tyrobp, 
truncated mouse Tyrobp (with both ITAM signaling motifs deleted) or a control vector were 
inserted in lentiviral expression plasmids containing an internal ribosome entry site (IRES) – 
enhanced green fluorescence protein (eGFP) sequence downstream of the Tyrobp expressing 
cassette (Fig. 2.3). Murine embryonic stem cell derived microglia (ESdM) were lentivirally 
transduced to overexpress Dap12/Tyrobp variants together with GFP or only GFP positive 
control vector, and then fluorescence-activated cell sorted (FACS) based on their GFP 
expression (Fig. 3.19).  
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Figure 3.19 – Mouse embryonic stem cell derived microglia (ESdM) were successfully transduced to 
overexpress full length mouse Dap12, truncated Dap12 or control vector. Cells were transduced 
using a vector containing expressing enhanced green fluorescent protein (eGFP) sequence 
downstream of the Tyrobp expressing cassette (encoding Dap12 variants). Fluorescence-activated 
cell sorting (FACS) of the successfully transduced ESdM cells was performed based on the GFP signal  
(analysis performed by Jens Kopatz, modified from Zhang, Gaiteri, Bodea et al., 2013). 
 
The mRNA expression profile of full length or truncated Dap12 overexpressing ESdM cells was 
compared with the results obtained in control cells and LOAD genome-wide gene-expression 
study (Fig. 3.20; Zhang, Gaiteri, Bodea et al., 2013). Several thousand DEG were identified in the 
Dap12 overexpressing ESdM cells (2638 DEG in full length Dap12 and 3415 DEG in truncated 
Dap12 overexpressing cells, FDR < 0.025). When compared with the LOAD brain tissue array 
data, approx. 1000 of these genes were found highly enriched (p < 10-15), recapitulating also 
previous AD features (Fig. 3.20a, Zhang, Gaiteri, Bodea et al., 2013). Elements enriched in full 
length Dap12 overexpressing ESdM were represented by Igam, Il18 (both already described as 
LOAD-related) or by Spp1 (secreted phosphoprotein 1; Fig. 3.20a). The elements enriched in 
truncated Dap12 overexpressing cells were more numerous and represented by already 
described LOAD-releated genes (e.g. interleukin 10 receptor α, Il10ra, or interleukin receptor 13 
α1, Il13a1) or by new elements (e.g. Cd84; Fig 3.20a; Zhang, Gaiteri, Bodea et al., 2013).   
Next, a large Bayesian network (approx. 8000 nodes) was created based on the mRNA 
sequencing results, revealing that the highest predictive power for DEG is found in close 
pathway proximity to Dap12/Tyrobp (Fig. 3.20b, Zhang, Gaiteri, Bodea et al., 2013).  
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Figure 3.25 – Full length or truncated Dap12/Tyrobp overexpressing ESdM cells recapitulate 
features of late onset Alzheimer’s disease (LOAD) human brains. a – Tyrobp connectivity with 
emphasis on DEG (FDR<0.05) in the transduced ESdM cells (full length Tyrobp – blue frame, 
truncated Tyrobp – red frame, common – mixed frame). The number of inputs is represented by 
node size. Previously described AD nodes depicted as squares; b – The significance of DEG predicted 
to be downstream of Tyrobp in transduced ESdM cells is negatively correlating with the pathway 
distance to Tyrobp in a large brain Bayesian network of approx. 8000 nodes (analysis in collaboration 
with Dr. Chris Gaiteri, Sage Bionetworks, Seattle, USA; published in Zhang, Gaiteri, Bodea et al., 
2013). 
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The study of functional categories enriched in the overexpressing Dap12 cells showed that 
approx 99% of the DEG from full length Dap12 cells were downregulated compared with the 
control vector cells, with an enrichment of genes involved in RNA metabolism (p < 10-4) and 
cell-cycle mitosis (p < 10-2). The cells overexpressing truncated Dap12 were presenting enriched 
up-regulated genes of vacuole/autophagy (p < 10-7) and mitochondrion (p < 10-3), and down-
regulated genes of the histone assembly pathway (p < 10-30). Among these results, 658 genes of 
the vacuole/autophagy pathway were down-regulated in the full length Dap12 overexpressing 
cells and up-regulated in the truncated Dap12 overexpressing cells (Zhang, Gaiteri, Bodea et al., 
2013).  
 
3.3.3 Amyloid-β (Aβ) Internalization by Functional Dap12 Overexpressing Microglial Cells 
 
AD pathology is characterized by the presence of amyloid-β (Aβ) plaques in the brains and it is 
hypothesized that microglial cells might be involved in the up-take and removals of Aβ via 
ITAM-related receptors (Gaikwad et al., 2009; Melchior et al., 2010). However, the possible role 
of the ITAM-bearing Dap12 adaptor molecule in this process was not analysed so far. 
Transduced ESdM cells were used to test the Dap12 involvement in the up-take of fibrillar Aβ. 
ESdM cells overexpressing full length Dap12, truncated Dap12 or a control vector were cultured 
in the presence of fibrillar Aβ or albumin as control and the up-take level was visualized via 
confocal microscopy (Fig. 3.21a). The internalized Aβ level was found significantly higher in the 
full length Dap12 overexpressing cells when compared with the Aβ up-take in the control cells 
(from 1.00 ± 0.07 relative units in the control cells to 1.28 ± 0.07 relative units in the full length 
Dap12 overexpressing cells, p < 0.01). The level of Aβ in the truncated Dap12 cells was 
significantly lower when compared with the Aβ up-take in the control cells (from 1.00 ± 0.07 
relative units in the control cells to 0.61 ± 0.06 in the truncated Dap12 overexpressing cells, p < 
0.001) (Fig. 3.21b). The albumin up-take was unaffected by the Dap12 overexpression, proving 
the up-take specificity of Aβ (Fig. 3.21c). 
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Figure 3.21 – Dap12 is required for amyloid-β (Aβ) phagocytosis by ESdM cells. a – Representative 
Z-stack confocal images of amyloid-β (red) and microglia marker Iba1 (green) immunostaining 
showing Aβ internalization. Scale bar: 10 µm; b – Full length Dap12 overexpressing cells present a 
higher level of Aβ internalization compared with control vector transduced cells, whereas truncated 
Dap12 overexpressing cells show an inhibition of Aβ up-take; c - Albumin up-take by transduced 
ESdM presents similar levels. n=3. 
 
The involvement of the ITAM signaling pathway in the up-take of Aβ was proven by 
measuring the phosphorylation level of spleen tyrosine kinase (Syk), an enzyme that is 
phosphorylated after recognizing activated ITAM motifs (C. Lowell, 2010). In this regard, 
Syk from Dap12 transduced cells treated with fibrillar Aβ was immunoprecipitated and 
used for western blot detection (Fig. 3.22a). The western blot quantification revealed a 
significantly increased level of Syk phosphorylation of full length Dap12 overexpressing 
cells in the presence of Aβ (from 0.45 ± 0.07 to 1.72 ± 0.33 relative units, p < 0.001), 
similar with the level reached in the control vector cells (1.62 ± 0.26 relative units; Fig. 
3.22b). However, the level of Syk phosphorylation in the truncated Dap12 treated with 
Aβ was not changed compared with the same cell type treated with PBS as control, and, 
moreover, significantly reduced compared with the other cell types (p < 0.05 vs. control 
cell treated with Aβ and p < 0.01 vs. full length Dap12 cells treated with Aβ (Fig. 3.22b). 
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Figure 3.22 – Amylid-β (Aβ) leads to phsosphorilation of spleen tyrosine kinase (Syk) via functional 
Dap12. a – Representative immunoblot picture of Syk (bottom) and phosphorylated-Syk (P-Syk; top) 
with or without 30 minutes (min) incubation with Aβ; b – Quantification of the immunoblot signal 
shows significant higher ratios of P-Syk/Syk in the presence of Aβ for the full length Dap12 
overexpressing cells, the truncated Dap12 cells being irresponsive to the treatment. n=3. 
 
3.3.4 Neuron Degeneration by Functional Dap12 Overexpressing Microglial Cells 
 
To explore possible ITAM-triggered effects on neuronal cells after Aβ up-take by microglia, 
transduced ESdM cells were co-cultured with primary mouse neurons in the presence or 
absence of Aβ (Fig. 3.23). First, analyzing the neurites length as neurotoxicity marker showed 
that primary neuronal cultures in the absence of microglia were irresponsive to Aβ (Fig. 3.23b). 
However, neurons were presenting shorter processes when microglia were added to the 
culture (form 1.05 ± 0.05 relative units reduced to 0.86 ± 0.03 relative units in the presence of 
microglia, p < 0.01; Fig. 3.23b). When Aβ is incubated together with the microglia-neurons co-
culture, the neurites length is further significantly decreased (from 0.86 ± 0.03 relative units in 
co-culture, to 0.57 ± 0.02 relative units when Aβ is added to the co-culture, p < 0.001; Fig. 
3.23b), supporting the idea of a microglia related neuronal toxicity.  
To investigate further the involvement of microglial ITAM-bearing Dap12 in neuronal toxicity in 
the presence of Aβ, primary neuronal cultures were incubated with Dap12 overexpressing cells 
(full length or truncated) or with control cells. Data showed that the control vector ESdM 
(expressing the constitutive functional Dap12) underent a decrease in neurites length from 0.86 
±0.03 relative units to 0.57 ± 0.02 relative units in the presence of Aβ (p < 0.001) and the full 
length Dap12 overexpressing cells – from 0.92 ± 0.05 to 0.58 ± 0.04 relative units in the 
presence of Aβ (p < 0.001; Fig. 3.23c). The primary neurons co-cultured with truncated Dap12 
were irresponsive to Aβ presence (Fig. 3.23c).  
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Figure 3.23 – Neuronal processes integrity is compromised by ESdM overexpressing functional 
Dap12, in the presence of Aβ. a – Representative immunocytochemistry images of primary neurons 
and transduced ESdM (control vector, Dap12 full length, Dap12 truncated) co-cultures in the 
presence of Aβ. Scale bar: 50 µm; b – The lengths of neuronal processes are shortened in co-culture 
with microglia only in the presence of Aβ; c – The neurites damage is increased in the presence of Aβ 
and control vector or full length Dap12 overexpressing ESdM. The neurotoxic effect is abolished in 
truncated Dap12 overexpressing ESdM. n.s. – not significant; n = 3. 
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3.3.5 Superoxide Release by Functional Dap12 Overexpressing Microglial Cells 
 
One of the microglia-related proposed pathways arising from the LOAD genome-expression 
analysis was having as endpoint members of the NADPH oxidase complex (Fig. 3.18). NADPH 
oxidase is an enzyme implicated in superoxide production as response to pathogen recognition 
by phagocytes, like microglia (Block, 2008). Therefore, the reactive oxygen species production 
in Dap12 overexpressing ESdM cells was assayed in the presence or absence of Aβ (Fig. 3.24a). 
Signal intensity quantification of DHE-labeled superoxide showed that control vector ESdM cells 
expressing the constitutive Dap12 were able to elicit a significant level of superoxide production 
(from 1.00 ± 0.09 to 1.43 ± 0.10 relative units in the presence of Aβ, p < 0.001; Fig. 3.24a). The 
full length Dap12 cells presented constitutively an increased level of superoxide production, 
thus the increase caused by Aβ presence was not significant compared with PBS treated cells, 
however the increase was significant in comparison with the PBS treated control cells (from 
1.00 ± 0.09 relative units in the control cells, to 1.55 ± 0.04 relative units in the Aβ treated full 
length Dap12 cells, p < 0.001; Fig 3.24a). The truncated Dap12 overexpressing ESdM cells were 
not presenting a constitutively increased level of superoxide production, nor were they able to 
produce additional superoxide in response to Aβ presence compared with PBS treated cells (Fig. 
3.24a). To prove the specificity of superoxide production to the Aβ, transduced cells were 
incubated with zymosan, as superoxide inducing reagent. Zymosan was able to increase the 
superoxide production in all the cell lines, proving that the NADPH functions were not altered in 
the Dap12 variants overexpressing cells (Fig 3.24b). Albumin was used as additional negative 
control, without having any effect on the supoxid production in all the transduced cell lines (Fig 
3.24b). 
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Figure 3.24 – Dap12 increases superoxide production specifically in the presence of Aβ. a – 
Representative pictures of control vector, full length or truncated Dap12 overexpressing ESdM cells 
in the presence or absence of amylodi-β and stained by the superoxide recognition agent 
dihydroethidium (DHE). Scale bar: 50 µm; b - Functional Dap12 increases the superoxide production 
of ESdM in the presence of Aβ, whereas truncated Dap12 is irresponsive to the Aβ presence; b – 
Release of superoxide is independent of Dap12 (full length or truncated) overexpressing ESdM in the 
presence of zymosan or albumin. n = 3. 
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4. Discussions 
 
 
 
 
The involvement of immunity in the neurodegenerative process mediated by brain microglial 
cells has been reported in many studies (Carson et al., 2006; Cunningham, 2013; Perry et al., 
2010). However, a detailed mechanism to explain the microglia-mediated neurodegeneration is 
still far from reach. Within this study, the involvement of the microglial TREM2/DAP12 pathway 
in two neurodegenerative disease was evaluated using in vitro and in vivo models. The TREM2 
receptor deficient mouse model of NHD was characterized in regard to microglial capacity to 
elicit a detrimental effect in the brain parenchyma, as reported in human NHD brains (Bianchin 
et al., 2010). Systemic inflammation was described as contributing to the increase of 
neurodegenerative susceptibility and/or cognitive decline in already diseased patients (Perry et 
al., 2007). To facilitate a better understanding of the involvement of systemic inflammation in 
the neurodegenerative process, two LPS treatment paradigms of mice were compared, proving 
the microglial involvement in dopaminergic degeneration, as found in PD (Miller et al., 2009). 
Based on a GWAS analysis of AD brains, DAP12 was identified as a key regulator of LOAD and its 
involvement in Aβ-related neurotoxicity was evaluated in vitro. The present study brings new 
evidences on the involvement of immunity in the neurodegenerative process, proposing 
mechanisms by which microglial DAP12 expression can correlate with neurotoxicity.  
 
4.1 The Effects of Microglial TREM2 Deficiency  
 
Loss of function mutations in TREM2 or its adaptor molecule DAP12 are associated in humans 
with the Nasu-Hakola disease (Paloneva et al., 2002, 2000). Within the present thesis, a mouse 
deficient of TREM2 was characterized in the absence or presence of inflammatory stimulation. 
The results revealed changes in microglial morphology in adult TREM2 KO mice together with 
alterations of transcripts levels in aged TREM2 KO animals without additional inflammatory 
stimulation. After intraperitoneal LPS application in mice, microglial morphological changes 
were more pronounced in adult TREM2 KO vs. WT controls. However, no changes in the 
proinflammatory mRNA levels were detected between TREM2 KO animals compared with WT 
controls. Integrating these results within the literature associated with TREM2 deficiency, it 
Discussions 
 
75 
 
seems that there is a different TREM2-related response mechanism in the CNS compared with 
the periphery.  
 
4.1.1 Involvement of TREM2/DAP12 Complex in Nasu-Hakola Disease 
 
Within this study, the characterization of the TREM2 KO mouse model of NHD was performed 
in regard to the brain microglial cell population. Since the TREM2 adaptor molecule DAP12 was 
discovered before TREM2, a higher amount of data on DAP12 was available, with many of the 
previous studies related to DAP12 deficiency. 
DAP12 protein was first reported as being expressed in NKs (Lanier et al., 1998) and shortly 
afterwards the group of Prof. Peltonen identified loss of function mutations in the DAP12 gene 
as being associated with the recessive autosomal disease NHD (Paloneva et al., 2000). The same 
study observed transcripts of DAP12 in microglial cells (Paloneva et al., 2000). The immune 
receptors TREM family was discovered in the same year by the group of Prof. Colonna and was 
proven to be expressed together with DAP12 in neutrophils and monocytes (Bouchon et al., 
2000). The correlation between loss of function mutations in TREM2 gene and NHD was 
observed two years later, when a study on macrophages and dentritic cells (DCs) expressing 
TREM2 confirmed the association between TREM2 and DAP12 proteins (Paloneva et al., 2002). 
Since then, the TREM2 and DAP12 molecules were studied in different in vitro and in vivo 
models, increasing the level of knowledge on microglial cells physiology both in healthy and 
pathological conditions. Today, NHD is considered to be the prototype of primary microglial 
disorder inside CNS (Bianchin et al., 2010). 
The main features of NHD are neuroinflammation and bone cysts (Bianchin et al., 2010; Kaneko 
et al., 2010a; Satoh et al., 2011a). As a result, some of the initial studies on DAP12 have focused 
on osteoclasts, cells of myeloid origin that are associated with bone resorption function. 
Continuing their pursuit, the group of Prof. Peltonen reported impaired differentiation and 
function of DAP12 or TREM2 deficient osteoclasts derived from peripheral blood mononuclear 
cells (PBMCs; Paloneva et al., 2003). These results were confirmed by other groups examining 
TREM2 or DAP12 KO osteoclasts differentiated from PBMCs or bone marrow derived 
monocytes/macrophages (BMDMs; Cella et al., 2003; Humphrey et al., 2006).  
Initial studies on DAP12 KO mice showed dysfunctions in the normal function of NKs and DCs 
(Tomasello et al., 2000) and inability of animals to develop autoimmunity due to impaired 
antigen priming (Bakker et al., 2000). After connecting NHD pathology with mutations in the 
DAP12 gene, evaluation of DAP12 KO mice reported features like osteopetrosis, thalamus 
hypolielinosis with synaptic degeneration and sensorimotor-related behavioral dysfunction 
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(Kaifu et al., 2003). However, these in vivo DAP12 KO mice data could not be confirmed by 
another group (Lanier, 2009).  
Unlike DAP12, the effects of TREM2 deficiency were initially studied to a lesser extent. In 
immature human DCs the crosslinking of TREM2 with antibodies led to increased MHC class II, 
CD86, CD40 and CCR7 expression (Bouchon et al., 2001). In primary mouse microglia cells only 
upregulation of CCR7, but not of MHC class II, CD86 or CD40 molecules was reported (Takahashi 
et al., 2005). CCR7 upregulation led to increased chemotaxis towards CCL19 and CCL21, both 
being ligands of CCR7 (Takahashi et al., 2005). Additionally, the same study reported the 
involvement of microglial TREM2/DAP12 complex in phagocytosis of apoptotic neurons without 
inflammation (Takahashi et al., 2005). The capacity of microglial phagocytosis inside CNS in the 
absence of inflammation is a crucial feature of nervous tissue homeostasis (Neumann et al., 
2008). Knock-down of TREM2 in microglia increased the transcription of proinflammatory genes 
like Tnfa, Nos2 and Il12p40, whereas overexpression of TREM2 did not changed the normal 
expression pattern of these genes (Takahashi et al., 2005). These results are in concordance 
with another study that reported enhanced TLR responses in Dap12 KO animals (Hamerman et 
al., 2005). Based on these results, it was concluded that TREM2 is involved in supressing the 
microglial proinflammatory reaction.  
 
4.1.2 TREM2 Deficient Mouse Characterization 
 
4.1.2.1 Age-related Changes in the mRNA of TREM2 Deficient Mice  
 
Within the present thesis, the previously described TREM2 KO mouse line (Turnbull et al., 2006) 
was used to explore the TREM2 deficiency inside CNS. It was showed previously that TLR 
stimulation of BMDMs from TREM2 KO and DAP12 KO mice increased the proinflammatory 
cytokine response (Turnbull et al., 2006). These findings confirmed previous results on DAP12 
KO BMDMs (Hamerman et al., 2005) and on TREM2 KD microglial cells (Takahashi et al., 2005). 
Moreover, in vivo studies of TREM2 KO mice, showed increased proinflammatory response in 
the periphery (Correale et al., 2013; Seno et al., 2009), whereas in WT animals, TREM2 
expression was increased on macrophages as response to challenge with the anti-inflammatory 
IL4 cytokine (Turnbull et al., 2006). 
Based on the above data, within this thesis the transcription levels of inflammatory-related 
genes were first evaluated in the brain of adult TREM2 KO and WT control mice. The chosen 
microglia-related genes were represented by Aif1 that encodes the microglial marker Iba1 
reported as being enriched in NHD brains (Satoh et al., 2011a), Tnfa and Il1b encoding typical 
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proinflammatory molecules released by activated immune cells and found also enriched in 
PBMCs from blood of NHD patients (Kiialainen et al., 2007). Additionally, since NHD pathology is 
also characterized by astrogliosis (Satoh et al., 2011a), transcription of astroglial marker Gfap 
was assayed. Intriguingly, 3 months old TREM2 KO animals showed no differences in the 
transcription of the above mentioned gene compared with matched WT controls. The same 
hold true for animals of 6 and 12 months. Only 24 months old animals showed differences 
between KO and WT controls mRNA levels in Aif and Il1b, indicating a slow progression of 
microglial dysfunction (Luo et al., 2010).  
It is known that NHD symptoms debut in the 20s or 30s (Kaneko et al., 2010a), thus it can be 
supposed that the mechanisms of in vivo microglia-related dysfunctions require a long time be 
triggered and the mouse model is not adequate for these experiments. Indeed, there are 
known human physiological processes in neurodegenerative diseases that cannot be fully 
mimicked by mouse models (Gilley et al., 2011; Götz and Ittner, 2008).  
 
4.1.2.2 Altered Microglial Morphology in TREM2 KO Mice  
 
In previous studies, dysfunctions of cellular activation due to either TREM2 or DAP12 deficiency 
were studied in the presence of inflammatory stimuli like IL1β (Paloneva et al., 2002) or LPS 
(Turnbull et al., 2006). In humans, NHD symptoms were initially observed in the 3rd decade of 
life (Kaneko et al., 2010a), thus it is tempting and plausible to presume that the NHD patients 
had suffered common inflammatory episodes before the onset of the disease. Moreover, 
systemic infections and inflammation were reported to correlate with chronic 
neurodegeneration (Perry et al., 2007). Therefore it was hypothesized that the TREM2 KO mice 
require an inflammatory stimulation to trigger similar microglial cytokine release as reported in 
NHD. For this, systemic intraperitoneal LPS challenges were administered to adult TREM2 KO 
and WT animals and the level of expression of several immune-related genes were measured in 
the mouse brains. Data showed that LPS elicited a normal response in WT animals, however no 
difference between TREM2 KO and WT animals was observed after LPS treatment.  
Upon stimulation, microglia undergo morphological changes that correlate with cellular 
activation (Kettenmann and Hanisch, 2011; Ransohoff and Perry, 2009). In human NHD brains, 
microglial are described only as being activated (Bianchin et al., 2010). However, no detailed 
study was performed on this aspect of the disease. Satoh and colleagues tried to tackle this 
aspect, but their results were inconclusive (Satoh et al., 2011a). Thus, within this thesis an in-
depth study of microglial phenotype in TREM2 KO vs. WT mice was performed. To evaluate the 
effects of systemic inflammation, groups of i.p. LPS treated TREM2 KO mice and appropriate 
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WT controls were used. In this regard, microglial cells within SNpr were fluorescently 
immmunostained with the specific marker Iba1 and quantified. SNpr is a substructure of the 
basal ganglia which were reported to be affected in NHD (Kaneko et al., 2010a). Moreover, 
SNpr was described as normally having an increased density of microglial cells (Lawson et al., 
1990), thus  SNpr  is a good area for exploring putative changes in microglial morphology. 
In TREM2 KO animals, microglial morphology was found to be altered compared with WT and 
vehicle treated animals. The microglial cell body area was smaller in TREM2 KO vs. WT mice, 
however, the number of microglial soma processes was found unchanged in TREM2 KO and WT 
mice as well as the branching number. A previous common concept of microglial physiology 
stated that activated microglia present a phenotype in which the number of microglial 
processes is decreased peaking with the amoebal morphology (Kreutzberg, 1996). Perry and 
colleagues improved this linear model of activation, proposing a more comprehensive model of 
microglial activation (Perry et al., 2007). In this model microglia can discriminate between 
different parameters of stimulation (e.g. intensity, interval of stimulation) eliciting different 
responses that can correlate with microglial morphology, although difficult to assess. One of 
these phenotypic states might be the one observed in the TREM2 KO vehicle treated animals. 
This ‘primed’ state of microglia was described as being a consequence of detection of changes 
in the parenchymal microenvironment, a common process in aged or diseased brain (Perry, 
2010). Systemic inflammation can trigger the switch of primed microglial physiology, tipping 
from a relatively benign phenotype towards a proinflammatory aggressive state (Perry, 2010). 
Indeed, in TREM2 KO and WT microglia, LPS treatment further increased the differences 
between the two genotypes. Microglial soma area in the LPS treated animals showed significant 
decrease in relation to the absence of TREM2, whereas Iba1 staining intensity increased, 
proving a shift towards a more activated microglial phenotype. Moreover, the number of soma 
processes in LPS TREM2 KO group was significantly decreased compared with the vehicle 
treated group of the same genotype further proving TREM2 deficiency-related microglial shift 
towards activation after inflammatory stimulation. These differences seen in microglial 
morphology after LPS treatment are in disagreement with a study in which the same LPS 
treatment protocol was used on WT animals and that claims an increase of microglial area 
accompanied by increase in number of processes after treatment (Chen et al., 2012). However, 
different anatomical areas were studied by Chen and colleagues (cortex and hippocampus) and 
moreover, on the experimental day 5 (Chen et al., 2012). Within this thesis, microglial cells 
were assayed in SNpr area at a later time point (experimental day 19). It can be hypothesised 
that microglia can adopt different morphological pheotypes subsequent to LPS treatment 
according to the brain localization. Evidences supporting this theory have come from other 
studies that identified different microglial subpopulations based on marker expression and 
response to activation (Chen et al., 2010; Scheffel et al., 2012). 
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The microglial morphological changes in LPS-treated TREM2 KO mice however, were not 
supported by upregulation of microglia-related proinflammatory genes (e.g. Tnfa or Il1b) above 
the level normally observed in LPS-treated WT mice. The incapacity of TREM2 KO mice to 
induce an increase of proinflammatory molecules transcription is in contradiction with previous 
in vitro reports on TREM2-related dysfunction (Takahashi et al., 2005; Turnbull et al., 2006) or 
GWAS of NHD PBMC derived DCs (Kiialainen et al., 2007; Satoh et al., 2011a). Besides the type 
and origin of the material mentioned in these studies, it has to be noted that no study on 
cytokines profile of NHD brains was reported and generally all NHD brain data are post-mortem 
analysis. This includes the fact that no transcriptomic or proteomic data are available 
throughout NHD development and thus interpreting the results obtained in TREM2 deficient 
mice might be difficult to correlate with the previous in vitro and human post-mortem data. 
As a potential additional readout of the TREM2-mediated microglial immunosupression, 
neuronal integrity of the dopaminergic system was investigated in TREM2 KO mice after i.p. LPS 
stimulation. Of note, SNpr is adjacent to the SNpc structure in which the somas of dopaminergic 
neurons are found. Many studies report LPS-triggered dopaminergic degeneration in vivo, as 
described in detail in the next subchapter of the thesis. It was hypothesised that the LPS-
triggered neurotoxicity could be elevated in microglia of TREM2 deficient mice due to absence 
of proinflammatory inhibition exercised by the TREM2 receptor (Takahashi et al., 2005). Data 
obtained revealed that all the LPS treatment groups were responsive to the LPS treatment by 
decrease in the number of TH positive cells in SNpc (data not shown). However, there was no 
difference observed between TREM2 KO and WT mice. These results might prove a TREM2 
independent neurotoxicity mechanism. In fact, in literature, TREM2 is considered to be part of 
the alternative (M2) activation markers (Ydens et al., 2012), thus it can be presumed that the 
expression of TREM2 is actually downregulated after the LPS treatment of WT mice towards 
levels encountered in the TREM2 KO animals. 
Many of the initial reports of TREM2 involvement in cytokines release come from either in vitro 
differentiated cells that might suffer expression changes due to the manipulation (Cella et al., 
2003; Hamerman et al., 2006; Paloneva et al., 2003; Turnbull et al., 2006) or primary mouse 
microglia cell cultures (Takahashi et al., 2005). On top of this, it is known that in vitro studies 
present only a snapshot of the entire complexity of the in vivo process and that in vivo 
genetic/functional compensation is an important mechanism in maintaining a stable condition. 
As reviewed by Barbaric and colleagues, mechanisms of genetic compensation were reported in 
mice in various loss of function studies, bringing forth the theory of genetic and functional 
robustness (Barbaric et al., 2007). 
In another line of in vivo studies, the involvement of TREM2 in ameliorating neuropathological 
conditions was shown. TREM2-mediated removal of apoptotic material and the capacity of 
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TREM2 to restrict the microglial proinflammatory cytokines release (Takahashi et al., 2005) led 
to inquiries on the capacity of TREM2 receptor to participate in ameliorating 
neurodegenerative diseases. MS is a human neurodegenerative disease characterized by axonal 
degeneration, demyelination and microglial activation (Compston and Coles, 2008). The mouse 
model of MS, the EAE model, was used to test the hypothesis of TREM2 involvement in 
ameliorating the disease (Takahashi et al., 2007). The study was able to recapitulate previous 
results by TREM2 overexpression in murine BMDMs and to present a non-invasive way of 
grafting the TREM2 positive myeloid cells at the site of lesion by intravenous administration 
(Takahashi et al., 2007). Additionally, TREM2 involvement in debris clearance in vivo, together 
with the active production of an anti-inflammatory milieu at the site of injury generally 
contributing to EAE disease amelioration were reported (Takahashi et al., 2007). The results of 
this study were further enforced by a simultaneous study presenting exacerbated pathology of 
EAE by antibody-mediated blocking of TREM2 (Piccio et al., 2007). However, in these studies, 
manipulation of TREM2 was performed either in vitro or pharmaceutically, thus potentially 
masking or exacerbating an otherwise undetected TREM2-related effect. 
TREM2 KO mice were successfully used in acute models of colon injury, evidentiating the 
involvement of TREM2 in mucosal wound repair (Correale et al., 2013; Seno et al., 2009). In the 
study of Seno and colleagues, absence of TREM2 receptor on macrophages led to diminished 
epithelial proliferation as response to experimental colon injury together with increase of Ifnγ 
and Tnfα proinflammatoy gene expression and decrease of Il4 and Il13 genes for cytokines 
implicated in alternative activation (Seno et al., 2009). In the analysis of Correale and 
colleagues, TREM2 deficiency conferred relative protection against colitis with less associated 
body weight loss, but also with lower levels of proinflammaotory cytokine production and 
bacterial killing capacity (Correale et al., 2013). Another in vivo proof of TREM2 implication in 
tissue repair came from an acute peripheral nerve injury study in which proinflammatory 
markers (Nos2, Ifnγ or Il12p40) were absent, but an increased level of tissue repair markers 
(arginase 1 and Ym1) were associated with an upregulation of TREM2 transcription (Ydens et 
al., 2012).  
In agreement with the colon wound repair study of Seno and colleagues (Seno et al., 2009), 
another study observed increased TREM2 transcription after injury, this time presened by 
stroke (Sieber et al., 2013a). However, when TREM2 KO mice were used, the acute 
inflammatory response (12 h after reperfusion) was very similar between TREM2 KO mice and 
littermate controls (Sieber et al., 2013a). Moreover, in the subacute phase (7 days reperfusion) 
and more evidently later (28 days) following stroke, TREM2 KO mice showed normal 
transcription of proinflammatory cytokines Tnfa, Il1a and Il1b (Sieber et al., 2013a). These 
results are in concordance with the present thesis in which no increase of microglial activation-
associated genes was observed. In view of these results, it is tempting to speculate on a 
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different response to TREM2 deficiency in the periphery vs. CNS, a phenomenon that might also 
explain the previous apparently contradictory in vitro data (Hamerman et al., 2005; Takahashi 
et al., 2005; Turnbull et al., 2006). 
 
4.2 Mechanisms of Neurodegeneration Triggered by Systemic LPS Application 
 
Systemic inflammation was associated with neurodegeneration in clinical studies (Perry et al., 
2007). In vitro and in vivo models of LPS challenges reported dopaminergic sensitivity via a 
process in which microglial cells play an important role (Cunningham, 2013; Miller et al., 2009). 
Here, two different systemic LPS treatment paradigms were compared to help identifying the 
specific microglial role within the neuronal dopaminergic loss. Transcriptome analysis revealed 
functions altered by LPS challenges, such as phagocytosis and complement-related immunity. 
By using a C3 deficient mouse line, the effects observed in LPS treated WT animals were 
abrogated, proving that the microglial involvement in dopaminergic loss is mediated via the 
complement system.  
 
4.2.1 Contribution of Systemic Inflammation to Neurodegeneration 
 
The application of inflammatory stimuli to trigger a response in TREM2 KO mice led to the 
search for a fast and reliable treatment paradigm of microglial activation.  
Microglial cell express a wide range of PRRs required for recognition of potentially dangerous 
molecules (Hanisch and Kettenmann, 2007). Bacterial LPS is one of the most common 
inflammatory molecules used in experiments and is known to be recognized by PRRs, namely by 
TLR4 found also on microglia where it induces a strong activation both in vitro and in vivo 
(Kettenmann, 2006; Perry, 2004; Rivest, 2003). Recently, Sceffel and colleagues observed that 
murine microglia reorganizes their response to TLR-mediated activation postnatally and that 
this process correlates with maturation of TLR4-organized functions (Scheffel et al., 2012). LPS 
recognition elicits convergent signaling cascades mediated by MAPK, NFkB or IRF to induce 
proinflammatory cytokines (e.g. TNFα, IL1β) or IFN extracellular release (Kawai and Akira, 
2006). Of note is that inflammation was correlated with neurodegeneration in various studies, 
as reviewed in Cunningham, 2013; Perry et al., 2007; Wyss-Coray and Rogers, 2012.    
Different models of microglial activation induced by LPS are widely used, many reporting 
specific degeneration of dopaminergic neurons as a result inside CNS (reviewd by Dutta et al., 
2008). Important aspects related with LPS administration is the route of administration and the 
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dosage. Based on previous studies (Cardona et al., 2006; Czapski et al., 2007), i.p. 
administration of LPS was used within this thesis in either repeated treatments over 4 
consecutive days with low dose of LPS (1 μg/gbw) or in a single treatment of a cumulative dose 
of LPS (4 μg/gbw).  
Peripheral immune system can communicate with the CNS via parallel direct and indirect routes 
(Dantzer et al., 2008; Perry et al., 2007; Skelly et al., 2013). The direct route follows the afferent 
vagal and trigeminal nerves or by molecules reaching brain parenchyma via BBB or physiological 
open brain structures, like the circumventricular organs (Dantzer et al., 2008; Perry et al., 2007). 
The indirect route is intermediated by the perivascular macrophages that recognize blood-
carried stimuli, eliciting an adequate response inside the brain parenchyma (Ek et al., 2001; 
Perry et al., 2007). However, if the BBB structure is altered, blood cells or molecules from 
periphery can enter the brain, affecting its normal function and activating microglia. This is the 
case for example in the EAE model, where macrophages and other immune cells from the 
periphery invade the CNS (Constantinescu et al., 2011), or serum molecules entering brain after 
injury (Adams et al., 2007).  
Yet the route of LPS communication with the CNS is debated (Cunningham, 2013). A study using 
radioactively-labeled LPS reported little evidence of BBB penetration (Banks and Robinson, 
2010). These finding were confirmed by another group that additionally observed increased 
LPS-related molecules in brain endothelial cells (Singh and Jiang, 2004), correlating with the 
indirect pathway of communication between brain and periphery. However, based on 
extavasation labeling with Texas red-conjugated dextran of 70 kDa, another study reported that 
BBB was disrupted after intravenous administration of LPS in mice (Ruiz-Valdepeñas et al., 
2011). 
Patients suffering from neurodegenerative diseases showed that episodes of peripheral 
inflammation triggered by infections lead to worsening of the clinical pathology (Combrinck et 
al., 2002; Perry et al., 2007). Moreover, the PD risk was significantly reduced by non-steroid 
anti-inflammatory drugs usage (Chen et al., 2005). Indeed, these observations were backed up 
by studies on dopaminergic neuronal loss triggered by experimental inflammation. LPS applied 
to mice has been reported to lead to dopaminergic degeneration with kinetics dependent on 
dosage and mode of administration (Dutta et al., 2008; Tufekci et al., 2011). A single injection of 
LPS directly within SN led to neuronal loss paralleled by dopamine decrease 21 days after 
injection (Castaño et al., 1998), together with the release of microglial cytokines (Arai et al., 
2004) and ROS production (Qin et al., 2004). The level of dopaminergic degeneration reached a 
plateau phase in ca. 8 weeks, whereas microglial activation gradually subsided (Liu, 2006). 
Systemic application of LPS, however, was reported to require longer time to achieve 
dopaminergic neuronal loss (7 months), but the process was progressive (Qin et al., 2007). 
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However, by using a repated treatment paradigm (4 daily doses of 1 µg/gbw LPS), Cardona and 
colleagues observed fast microglial activation and neuronal loss in Cx3cr1 deficient mice 
(Cardona et al., 2006). 
 
4.2.2 Complement Involvement in Dopaminergic Neurodegeneration 
 
4.2.2.1 Microglial Activation and Dopaminergic Degeneration Triggered by Systemic LPS 
Application in Mice 
 
The results of Cardona and colleagues (Cardona et al., 2006) were successfully replicated within 
the present thesis by systemically injecting LPS in adult mice. Data showed significantly 
decreased numbers of TH positive cells after 19 days, but only by using repeated i.p. treatments 
of low dose LPS (1 μg/gbw) over 4 consecutive days. A single cumulative dose of LPS (4 μg/gbw) 
was not able to reach the same level of dopaminergic loss within 19 days. However, it is 
probable that the single treatment paradigm requires a longer time period to achive 
dopaminergic degeneration, as reported previously (Qin et al., 2007). In conformity with other 
studies (Nguyen et al., 2013; Qin et al., 2007), the decrease in TH specific marker accurately 
described dopaminergic loss and not only a decrease of TH production, as proven by using 
another neuronal specific marker (NeuN) that led to the same pattern of neuronal loss.  
Brain inflammatory response to peripheral LPS application was assayed initially by investigating 
microglial specific gene Aif1. Data showed a fast microglial response by upregulation of Aif1 
gene mRNA on the experimental day 5 after the initiation of repeated or single LPS treatment. 
However, when assayed on day 19, Aif1 mRNA was found to be drecreased to similar levels as 
registered in vehicle controls. These results were confirmed at protein level by IHC analysis, 
when Iba1 reactivity was observed to be increased initially and returned to basal level on 
experimental day 19. A similar pattern of microglial activation was observed in the mRNA levels 
of other microglia activation markers, like Tnfa, Il1b and Nos2. Of note, the only gene that 
presented a significant increased expression level on day 19 was Il1b, but only after repeated 
treatment. A possible explanation for this outcome would be the autocrine properties of Il1β 
(Toda et al., 2002) that could contribute to its further release for a longer period of time. Il1β 
has higher potency compared with other cytokine: experimentally Il1β is required in a much 
lower amount for reaching similar effects as the ones observed for example after LPS treatment 
(Skelly et al., 2013).  
84 
 
To further prove the differences between the LPS treatment paradigms, Tnfα and Il1β proteins 
were measured inside the brain on experimental day 5 and were significantly increased in the 
repeated compared to single treatment. The transient activation of microglia, similar to the 
acute-phase response in the periphery, with fast increase of activation markers directly after 
LPS treatment which were lost in several days, was also reported in several other studies, as 
reviewed by Liu (Liu, 2006). Tolerance to subsequent LPS challenges was previously observed in 
the periphery (Nomura et al., 2000). To investigate this aspect, Tnfα and Il1β in blood plasma 
were quantified after LPS challenges and were found to be similar after both single and 
repeated treatments, in concordance with the study of Nomura and colleagues (Nomura et al., 
2000). Altogether, these data evidentiate brain vs. periphery differences in the induction of 
tolerance after succesive LPS challenges, in accordance with older studies (Faggioni et al., 1995; 
Püntener et al., 2012). 
 
4.2.2.2 Enriched Immune-related Transcripts in Mice Systemically Treated with LPS 
 
To identify key players in the mechanism of microglial activation subsequent to repeated LPS 
i.p. application involved in dopaminergic degeneration, a microarray study of brains of LPS 
treted mice was performed. The array analysis showed higher gene enrichment after the 
repeated treatment paradigm compared with the single treatment paradigm. The majority of 
the genes were found to be upregulated. Interestingly, Hbb-a1 and Hbb-a2 (encoding for α- and 
β-hemoglobin) were the only significantly downregulated genes and they were specific to the 
repeated treatment paradigm. It was previously proven in mice, rats and humans that 
dopaminergic neurons express hemoglobin, with a role in mitochondrial and oxygen related 
functions within the neurons (Biagioli et al., 2009). Diffrences between the time-span of the last 
LPS challenge and the time of tissue collection (4 days for the single treatment and 1 day for the 
repeated treatment) might explain the variation observed in the number of DE genes between 
the trateatment paradigms. However, the identification of specific DE genes elicited by the LPS 
treatment can provide an insight on the mechanism of dopaminergic degeneration.  
To identify significant biological functions related with the array data, pathway analysis was 
performed with a higher stringency on the DE genes. The most enriched pathways were found 
to be microglia-related (e.g. enrichment of the immune cell trafficking pathway, inflammatory 
response pathway, inflammatory disease pathway). Within these pathways, the majority of 
genes were found to be DE in the repeated treatment paradigm (58 genes) compared with the 
single treatment paradigm (3 genes). Only 22 genes were found to be common to both 
treatment paradigms. A more detailed analysis of the DE genes identified the phagosome 
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together with the complement and coagulation cascades as being the most prevalent functions 
activated by the LPS challenges.  
Indeed, under both healthy and pathological conditions, one of the main functions of microglia 
is phagocytosis (Brown and Neher, 2012; Neumann et al., 2008; Sierra et al., 2013). In the 
phagosome-releated genes, the array data identified the complement component C3, the 
integrin subunit Itgam of the CR3, the common γ-chain (encoded by the Fcer1g gene), and the 
NADPH members p22phox (coded by the Cyba gene) and gp91phox (coded by the Cybb gene). 
The array data were also confirmed by sqRT-PCR. Interstingly, all these genes and/or proteins 
were previously correlated individually with different neurodegenerative processes or 
dysfunctions. Deficiency in CR3 leds to abnormalities in the normal development of the optic 
nerve due to an absence of microglia-mediated phagocytosis (Schafer et al., 2012). 
Interestingly, CR3 signals via DAP12 to induce phagocytosis followed by respiratory burst 
(Ivashkiv, 2009), however Tyrobp was not found significantly increased. On the other hand, 
Fcer1g mRNA of the common γ-chain, which is also an adaptor protein containing an ITAM 
motif and very similar in structure with DAP12, was increased by the LPS treatment. The 
involvement of Fcer1g in neurodegeneration was previously described (Lunnon et al., 2011). 
Other studies have also reported partial protection of Fcer1g KO animals against dopaminergic 
degeneration (Cao et al., 2010) or even irresponsiveness to the application of dopaminergic-
specific toxin MPTP (Lira et al., 2011). The involvement of NADPH in dopaminergic degeneration 
was previously reported (Choi et al., 2012; Qin et al., 2013; Wu et al., 2002). Interestingly, the 
organisation and activation of NADPH is also downstream of ITAM bearing molecules (Colonna, 
2003; Ivashkiv, 2008). 
 
 
4.2.1.3 The Contribution of Complement Component 3 in LPS-induced Dopaminergic 
Degeneration 
 
The complement system involvement in neurodegeneration was vastly investigated in previous 
studies. Complement proteins are produced mostly in the liver and are present at high levels in 
serum, but glial cells and neurons in the CNS can synthesize these proteins as well (Wyss-Coray 
and Rogers, 2012). Moreover, levels of complement molecules are increased after brain injury 
or neurodegeneration (Gasque, 2004). In PD, C1q was associated with labeling and clearance of 
neuromelanin (Depboylu et al., 2011). Another study observed intraneuronal and extraneuronal 
Lewy bodies and dendritic spheroid bodies stained for C3d, C4d, C7, and C9 in the SNpc of PD 
brains (Yamada et al., 1992).  
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Within this thesis, a careful analysis of the complement pathway after repeated LPS teatment 
revealed the important role payed by C3. Thus, it was hypothesised that in the absence of C3 
the effects of microglial activation on neuronal degeneration might be inhibited. For this, C3 KO 
animals were injected with LPS using the repeated treatment paradigm and the loss of SNpc 
dopaminergic neurons was evaluated. The results confirmed the hypotheis. In C3 KO mice 
neuronal loss was significantly less compared with WT animals. In previous studies, C3 was 
demonstated to contribute to microglial priming towards a proinflammatory state (Ramaglia et 
al., 2012). Additionally defficiency in another complement-related protein, the C3 convertase 
regulator complement receptor 1-related protein (Crry), leds to increased cleavage of C3 into 
the active products C3b and iC3b sensitizing microglia to systemic LPS (Ramaglia et al., 2012). 
Interestingly, in a mouse model of AD, Crry-mediated inhibition of C3 activation of microglia 
increased the amyloid plaques deposition and neuronal degeneration (Wyss-Coray and Yan, 
2002), providing another evidence of microglial implication in neurodegenerative diseasese. 
 
4.3 DAP12/TYROBP Involvement in LOAD 
 
Different genes, together with epidemiological and psychosocial factors were previously correlated with 
LOAD (Bettens et al., 2013; Qiu et al., 2010). Within this thesis, a broad GWAS on LOAD brain and non-
demented controls was conducted, identifying TYROBP (the gene encoding for DAP12) as a key regulator 
of LOAD. Overexpression of functional or non-functional DAP12 variants in microglial cells recapitulated 
LOAD-associated transcriptomic features and revealed its implications in Aβ-related pathology. In vitro 
results pointed out the requirement of functional DAP12 for Aβ internalization by microglia and for 
subsequent release of intracellular signaling cascades. Aβ-associated neurotoxicity was evidentiated on 
neurons in cocultures only when functional microglial DAP12 was present. Release of toxic superoxide, 
one of the functions downstream of DAP12, was proven to be abolished in non-functional DAP12 
overexpressing cells. Results propose an Aβ-related neurototoxic pathway mediated by microglial 
DAP12. 
 
4.3.1 The Genetic Background of LOAD 
 
Many of the potential disease mechanisms reported in AD, and particularly in sporadic LOAD, 
were centered on Aβ-related pathology. Recently, multidisciplinary studies in epidemiology, 
neuropathology and neuroimaging have provided evidences which support the role of vascular 
factors and related disorders (like high blood pressure, obesity, diabetes, cerebral 
microvascular lesions and smoking) as risk factors and the possible role of psychosocial factors 
(like high educational achievements, mentally-stimulating activity, social engagement and 
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physical exercise) as protective factors in the development and clinical manifestation of the 
dementia syndrome, including AD (Qiu et al., 2010). However, before this multidisciplinary 
approach, other groups reported genetics that are involved in LOAD debut and progression 
with the highest odds ratio gene being found for the APOE (Corder et al., 1993). As the GWAS 
technique advanced, a multitude of additional susceptible risk loci were identified (Bettens et 
al., 2013).  
 
4.3.2 Mechanisms of DAP12 Mediated Neurotoxicity in LOAD 
4.3.2.1 DAP12 Revealed as Key Regulator by Transcriptome Analysis of LOAD  
 
Excepting the APOE gene that accounts for at least 30% of genetic variance (Corder et al., 
1993), the correlation of these susceptible loci with LOAD is very small. It can be hypothesized 
that other fraction of the genetic variance might be implicated in the development of the 
disease. Based on this, within this thesis, a GWAS was performed on more than 1500 brains of 
patients suffering from LOAD or non-demented controls. These GWAS results were found to be 
correlat with known dysfunctions of the cell cycle, mitochondrion and autophagy, as reported 
previously in LOAD (Coskun et al., 2004; Webber et al., 2005). Additionally, present GWAS 
network revealed the immune/microglia cluster to be predominate in the LOAD brains, in 
agreement with previous results (Bettens et al., 2013). 
Indeed, microglial involvement in AD was investigated by many groups using different 
techniques (El Khoury and Luster, 2008; González-Scarano and Baltuch, 1999; Perry et al., 2010, 
2007; Wyss-Coray and Rogers, 2012). The GWAS presented in this thesis, reported an 
immune/microglia related cluster found among others of ITGAM, FCGR1 and TREM2 genes 
encoding for receptors that were correlated previously with AD. Thus, ITGAM gene encodes the 
αMβ2-integrin, part of the CR3. Complement was reported to be activated in the AD brain (Shen 
et al., 2001) and a more recent transcriptome analysis have also identified enrichements of the 
complement genes in AD (Blalock et al., 2004; Katsel et al., 2009). Of note, C1q, the initiatior of 
the classical complement pathway was found to be associated with plaques in AD brains 
(Fonseca et al., 2004) and was also found enriched within the present LOAD GWAS. FCGR1 gene 
encodes the immunoglobulin G Fc receptor (CD64) and was recently implicated in the 
development of hypercholestrolaemia-associated features of AD (Fernandez-Vizarra et al., 
2012). TREM2 receptor was also reported as being found in the proximity of Aβ plaques, raising 
questions regarding its function in AD (Frank et al., 2008; Melchior et al., 2010). Recently, 
TREM2 was associated with LOAD in two individual system biology studies with odds ratios 
similar with the ones of APOE (Guerreiro et al., 2013; Jonsson et al., 2013).  
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4.3.2.2 DAP12 Modified Microglial Cells Recapitulate Features of LOAD  
 
TREM2 relies on DAP12 for intracellular signaling (Colonna, 2003). Within the GWAS analysis of 
the thesis, TYROBP (encoding DAP12) was identified as key regulator of the immune/microglia 
cluster in LOAD brains. Moreover, most of the major proteins downstream of DAP12 were also 
found to be enriched. Since DAP12 is involved in signaling towards actin reoganisation (related 
with process of phagocytosis and migration) and NADPH oxidase activation (related with the 
oxidative-burst), these functions were hypothesized to be altered in the LOAD brain.  
ESdM cells are a microglial cell line generated in vitro from mouse embryonic stem cells via a 
five step protocol of differentiation (Beutner et al., 2010). ESdM were fully characterized and 
they showed a microglial phenotype and transcriptome similar with mouse primary microglia 
and clearly different from other brain cell types or macrophages (Beutner et al., 2013, 2010). 
Transcriptome analysis of the ESdM overexpressing DAP12 variants showed a highly similar 
pattern with the results of LOAD brain, thus validating the working system. To identify possible 
DAP12-related dysfunctions in AD brains, ESdM cells were lentivirally transduced to 
overexpress either full length functional DAP12, truncated non-functional DAP12 (in which the 
ITAM signaling motif was deleted) or a control vector. The backbone vector was designed to 
present a GFP expressing cassette, thus the overexpressing cells were selected based on the 
GFP signal.  
 
4.3.2.3 DAP12-mediated Mechanism of Aβ-triggered Neurotoxicity 
 
Among the variety of PRRs expressed by microglia, a number of them were reported as 
implicated in microglial recognition and/or phagocytosis of Aβ, like TLRs, RAGE, scavenger 
receptor A, signal regulatory protein β1 (SIRPβ1), CR3, or a multicomplex structure formed of 
CD36, α6β1-integrin and CD47 (Gaikwad et al., 2009; Mandrekar and Landreth, 2010; Wyss-
Coray and Rogers, 2012). DAP12 is an adaptor molecule for at least two of the receptors 
implicated in Aβ recognition and/or internalization, as it was demonstrated in vitro for SIRPβ1 
(Gaikwad et al., 2009) and in vivo for CR3 (Fu et al., 2012). Based on these informations, it was 
hypothesised that Dap12 might be of vital importance for intracellular signaling after Aβ 
engagement. Indeed, by using Dap12 variants overexpressing cells it was proved that the level 
of Aβ was upregulated in microglial cells when functional Dap12 was present, whereas 
dysfunction in Dap12 signaling led to decreased internalization. Moreover, full length 
overexpression of Dap12 increased the phagocytosis level of Aβ in microglial cells. When using 
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albumin as control, the level of internalisation was similar between all the cell types, proving 
Dap12 specificity in the microglial uptake of Aβ. 
After Dap12 activation, Syk is phosphorylated, releasing intracellular activatory signaling 
cascades, one of them increasing the capacity of cellular phagocytosis (Ivashkiv, 2009; Mócsai 
et al., 2010; Turnbull and Colonna, 2007). Thus, as additional proof of Dap12 involvment in Aβ 
uptake, the level of Syk activation in the Aβ treated microglial cells was explored. Results 
confirmed the activated Syk after Aβ application to the microglial culture in cells overexpressing 
functional Dap12, whereas Syk activation was not detected in truncated Dap12 overexpressing 
cells. Syk activation was previously correlated with AD (McDonald et al., 1997) and recent 
reports evidentiat Syk involvement also in tau protein hyperphosphorylation (Lebouvier et al., 
2009). Of note, Syk is crucial for initiation of ITAM-signaling receptors (Lowell, 2010) and thus it 
can be presumed that DAP12 is not the only molecule enhancing Syk activation in AD. 
Additionally, due to its position within the signaling pathway, Syk is another bottleneck 
molecule that can modulate the activity of immune cells (Lowell, 2010). Recent studies 
reported Syk involvement in adaptive immunity, cellular adhesion, innate immune recognition, 
osteoclast maturation, platelet activation and vascular development (Mócsai et al., 2010).  
The overactivated microglial neurotoxicity was reported by many studies (Kettenmann and 
Hanisch, 2011; Ransohoff and Perry, 2009) as being closely related also with the presence of 
amyloid plaques inside the AD brain (Wyss-Coray and Rogers, 2012). Microglia are known to be 
more abundant in the white matter of brain (Lawson et al., 1990), thus an overactivation of 
microglia can easily lead to associated neurodegenerative dysfunctions (Cunningham, 2013). 
The effect of Aβ on Dap12 overexpressing ESdMs was assayed in mouse primary neuronal 
culture. First the effect of microglia, amyloid or a combination of both was investigated, 
observing that only when all are added to the culture, a significant change in the length of 
neurites can be detected. This result provides evidence of microglial mediated neurotoxicity in 
the presence of Aβ, a process that was previously described also by other studies (Maezawa et 
al., 2011; Murgas et al., 2012; von Bernhardi et al., 2007; Zhang et al., 2011). However, when 
microglia overexpressing Dap12 variants were added to the neuronal culture, a reduction of 
neurite lengths correlated with the presence of Aβ together with a functional Dap12 in 
microglial cells was detected. Non-functional truncated Dap12 abrogated the neurotoxic effects 
of Aβ treated micriglia, proving the involvement of Dap12 signaling pathway in microglial 
neurotoxicity. Indeed, the signaling pathway related with Aβ induced neurotoxicity was 
previously reported to involve CR3 and PI3K (Zhang et al., 2011), LPS receptor component CD14 
(Liu et al., 2005), scavenger receptors (Bamberger et al., 2003; Murgas et al., 2012), caspase 
(Burguillos et al., 2011) and NADPH (Block, 2008). Many of these molecules were found within 
or close proximity of the DAP12 signaling cascade.  
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One of the processes activated by the DAP12 pathway is superoxide production via NADPH 
oxidase complex recruitment (Colonna, 2003; Ivashkiv, 2009). Microglia, like all phagocytic cells, 
can provide host defense by ingesting microbes and destroing them by different mechanisms, 
including the generation of NADPH oxidase-mediated ROS (Block et al., 2007). However, many 
studies reported dysfunctions or side-effects of this process, when microglial NADPH oxidase 
exceeds its protective effect and becomes detrimental for brain parenchyma (Block, 2008). 
Thus, NADPH-related oxidative stress was described in diseases like PD (Choi et al., 2012; Hunot 
et al., 1996) or AD (Block, 2008; Zhang et al., 2011), but as well in the normal process of ageing 
(Qin et al., 2013). Based on these reports, the release of superoxide mediated by Dap12 was 
investigated next in microglial cells overexpressiong variants of Dap12 in the presence or 
absence of Aβ. The results show that indeed ROS production is increased in microglial cells in 
the presence of Aβ only when a functional Dap12 is present in the system, the truncated 
overexpressoin of Dap12 presenting no effect on superoxide release. To verify the specificity of 
the Dap12-mediated pathway in superoxide release after Aβ stimulation, the cells were 
incubated with another potent superoxide inductor zymosan (agonist of TLR2) or albumin, 
which was proven previously to be internalized by microglial cells independent of Dap12. Under 
these stimuli, the production of superoxide is not influence by the presence of different Dap12 
variants overexpressed in microglial cells.  
Thus, it can be concluded that microglial release of superoxide after Aβ stimulation is mediated 
via activation of the Dap12 adaptor molecules.  
 
4.4 Summary 
 
Microglia, the resident immune cells of the CNS, were described as presenting both 
neuroprotective and neurotoxic functions, depending on stimulation and/or brain physiological 
condition (Biber et al., 2007; Ransohoff and Perry, 2009). Nasu-Hakola disease (NHD) is 
considered to be the prototype of primary microglial disorder inside brain (Bianchin et al., 
2010), but microglial involvement has been described in essentially all the major 
neurodegenerative diseases (Cunningham, 2013; Minghetti, 2005; Perry et al., 2010). However, 
the intimate physiology that drives microglial changes from a beneficial to a detrimental cell 
type for the brain parenchyma is not fully understood. 
Within the present thesis, microglial physiology was assessed in models of different 
neurodegenerative diseases such as NHD, Parkinson’s disease (PD) or late onset Alzheimer’s 
disease (LOAD). 
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NHD is known to be caused by loss of function mutation in either triggering receptor expressed 
on myeloid cells 2 (TREM2) or its associated molecule DNAX-activating protein of molecular 
mass 12 kDa (DAP12) (Paloneva et al., 2002, 2000). By using a NHD mouse model to asses the 
implications of microglial TREM2 deficiency for the brain parenchyma, here was observed for 
the first time age-dependent changes in microglia-related gene expressions. Data obtained in 
this thesis identified an increase of immune-related genes like Il1b and Aif1 in 24 months old 
TREM2 knock-out (KO) vs. wild type (WT) mice. However, when bacterial toxin 
lipopolysaccharide (LPS) was applied to the TREM2 KO mice, the obtained response was similar 
with the one elicited in normal WT control mice. These results are contradictory at first sight 
with previous in vitro studies (Hamerman et al., 2005; Takahashi et al., 2005) or in vivo studies 
on macrophages or models of experimental colitis (Correale et al., 2013; Seno et al., 2009; 
Turnbull et al., 2006). These studies report an increase of cytokines in TREM2 deficient models. 
However, until present, only one other study has assessed TREM2 deficieny inside the brain 
(Sieber et al., 2013b). Siber and collegues used TREM2 KO mice in a model of stroke, confirming 
the results obtained in this thesis (Sieber et al., 2013b). Thus, based on these data, it can be 
hypothesized that TREM2 is presenting a different response in CNS compared with the 
periphery, where TREM2 deficiency seem to lead to increase of proinflammatory cytokines 
after inflammatory stimulation (Correale et al., 2013; Seno et al., 2009). 
Microglial cells present an important contribution to LPS-induced dopaminergic degeneration 
both in vitro and in vivo, but the exact mechanism of degeneration is not fully known 
(Cunningham, 2013; Dutta et al., 2008). To bring more data on the microglial-mediated 
neurodegeneration, two models of systemic LPS application in mice were compared here, one 
based on a repeated intraperitoneal (i.p.) application and the other on a single i.p. application 
of the same total cumulative dose of LPS. Only the repeated LPS treatment paradigm was able 
to produce fast dopaminergic degeneration. To characterize the mechanism involved in this 
process, transcriptome array was performed, comparing the two treatment paradigms. Further 
pathway analysis showed enrichment of the microglial phagosome, oxidative burst and 
complement cascade-related functions after the repeated LPS treatment of mice. To explore 
the complement involvement in the dopaminergic neurons loss, C3 KO animals were challenged 
according to the LPS treatment paradigm and proved to be resistant to neuronal loss. The 
results presented in the thesis bring further insights into microglia-mediated dopaminergic 
degeneration, providing ground for possible future treatment strategies.  
Complex multifactorial diseases as LOAD require careful analysis for the identification of causal 
factors (Bettens et al., 2013; Qiu et al., 2010). Within the present thesis, a genome wide 
association study was performed on a group of more than 1500 LOAD brains and non-
demented controls. TYROBP (encoding DAP12) was identified as key regulator of the disease. 
Overexpression of functional or non-functional DAP12 (without signaling motif) in microglial 
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cells recapitulated features of LOAD in an array analysis. Studies on the DAP12-associated 
microglial functions evidentiated the involvement of DAP12 in previously described aspects of 
LOAD pathology such as microglial Aβ phagocytosis, neuronal toxicity in the presence of Aβ and 
release of superoxide. The present thesis proposes a microglial DAP12-mediated neurotoxicity 
triggered by the presence of Aβ that can contribute to the development LOAD neuropathology. 
Thus, the present thesis proposes a microglial-related mechanism in which different immune-
related pathways are converging and thus contributing to the neurodegenerative processes.  
 
Appendix 
 
93 
 
Appendix 
Specific genes enriched by the repeated (4x) LPS challenges of mice. FC ≥ 2, FDR < 0.05. 
Symbol Gene 
AI607873  expressed sequence AI607873  
AW112010  expressed sequence AW112010  
Acer2  alkaline ceramidase 2  
Aoah  acyloxyacyl hydrolase  
Apobec3  apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide 3  
C1qb  complement component 1, q 
subcomponent, beta polypeptide  
Cav1  caveolin 1, caveolae protein  
Ccl3  chemokine (C-C motif) ligand 3  
Cd33  CD33 antigen  
Cd53  CD53 antigen  
Cd68  CD68 antigen  
Cd72  CD72 antigen  
Cd93  CD93 antigen  
Clec4a1  C-type lectin domain family 4, member 
a1  
Clec4a3  C-type lectin domain family 4, member 
a3  
Cp  ceruloplasmin  
Ctsc  cathepsin C  
Ctsh  cathepsin H  
Cxcl13  chemokine (C-X-C motif) ligand 13  
Cyba  cytochrome b-245, alpha polypeptide  
Eltd1  EGF, latrophilin seven transmembrane 
domain containing 1  
Eng  endoglin  
Fcer1g  Fc receptor, IgE, high affinity I, gamma 
polypeptide  
Fcgr2b  Fc receptor, IgG, low affinity IIb  
Fcgr3  Fc receptor, IgG, low affinity III  
Fcgr4  Fc receptor, IgG, low affinity IV  
Fn1  fibronectin 1  
Gbp2  guanylate binding protein 2  
H2-D1  histocompatibility 2, D region; 
histocompatibility 2, D region locus 1  
  
  
Symbol Gene 
H2-Q6  histocompatibility 2, Q region locus 1; 
histocompatibility 2, Q region locus 9; 
similar to H-2 class I histocompatibility 
antigen, L-D alpha chain precursor; 
histocompatibility 2, Q region locus 8; 
histocompatibility 2, Q region locus 2; 
similar to MHC class Ib antigen; 
histocompatibility 2, Q region locus 7; 
histocompatibility 2, Q region locus 6; 
hypothetical protein LOC100044307; 
similar to H-2 class I histocompatibility 
antigen, Q7 alpha chain precursor (QA-
2 antigen); RIKEN cDNA 0610037M15 
gene  
H2-Q7  histocompatibility 2, Q region locus 1; 
histocompatibility 2, Q region locus 9; 
similar to H-2 class I histocompatibility 
antigen, L-D alpha chain precursor; 
histocompatibility 2, Q region locus 8; 
histocompatibility 2, Q region locus 2; 
similar to MHC class Ib antigen; 
histocompatibility 2, Q region locus 7; 
histocompatibility 2, Q region locus 6; 
hypothetical protein LOC100044307; 
similar to H-2 class I histocompatibility 
antigen, Q7 alpha chain precursor (QA-
2 antigen); RIKEN cDNA 0610037M15 
gene  
Ifi204  interferon activated gene 204  
Ifi30  interferon gamma inducible protein 30  
Ifit1  interferon-induced protein with 
tetratricopeptide repeats 1  
Ifit3  interferon-induced protein with 
tetratricopeptide repeats 3  
Igfbp7  insulin-like growth factor binding 
protein 7  
Il2rg  predicted gene 614; interleukin 2 
receptor, gamma chain  
Itgam  integrin alpha M  
Lcp1  lymphocyte cytosolic protein 1  
Lcp2  lymphocyte cytosolic protein 2  
Lgals3bp  lectin, galactoside-binding, soluble, 3 
binding protein  
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Lilrb4  glycoprotein 49 A; leukocyte 
immunoglobulin-like receptor, 
subfamily B, member 4  
Ly6a  lymphocyte antigen 6 complex, locus A  
Ly86  lymphocyte antigen 86  
Mpeg1  macrophage expressed gene 1  
Ms4a6b  membrane-spanning 4-domains, 
subfamily A, member 6B  
Ms4a6d  membrane-spanning 4-domains, 
subfamily A, member 6D  
Ms4a7  membrane-spanning 4-domains, 
subfamily A, member 7  
Pglyrp1  peptidoglycan recognition protein 1; 
similar to peptidoglycan recognition 
protein  
Pilra  paired immunoglobin-like type 2 
receptor alpha  
Prg4  proteoglycan 4 (megakaryocyte 
stimulating factor, articular superficial 
zone protein)  
Ptprc  protein tyrosine phosphatase, receptor 
type, C  
Stab1  stabilin 1  
Tgtp1  T-cell specific GTPase 2; T-cell specific 
GTPase  
Tlr13  toll-like receptor 13  
Trim30  tripartite motif-containing 30  
Tyrobp  TYRO protein tyrosine kinase binding 
protein  
Unc93b1  unc-93 homolog B1 (C. elegans)  
 
 
Common genes enriched by the repeated (4x) and single (1x) LPS challenge of mice. FC ≥ 2, 
FDR < 0.05
Symbol Gene 
C1qa complement component 1, q 
subcomponent, alpha polypeptide 
C1qc complement component 1, q 
subcomponent, C chain 
C3 complement component 3; similar to 
complement component C3 
prepropeptide, last 
C3ar1 complement component 3a receptor 1 
C4b similar to Complement C4 precursor; 
complement component 4A (Rodgers 
blood group); similar to complement C4; 
complement component 4B (Childo 
blood group) 
Ccl5 chemokine (C-C motif) ligand 5 
Cd52 CD52 antigen 
Ctss cathepsin S 
Cybb cytochrome b-245, beta polypeptide 
Symbol Gene 
Emr1 EGF-like module containing, mucin-like, 
hormone receptor-like sequence 1 
Fyb FYN binding protein 
Wfdc17 WAP four-disulfide core domain 17 
H2-K1 histocompatibility 2, K1, K region; similar 
to H-2K(d) antigen 
Ifitm3 interferon induced transmembrane 
protein 3 
Igsf6 immunoglobulin superfamily, member 6 
Lcn2 lipocalin 2 
Lyz2 lysozyme 2 
Ms4a6c membrane-spanning 4-domains, 
subfamily A, member 6C 
Pld4 phospholipase D family, member 4 
Saa3 serum amyloid A 3 
Serpina3n serine (or cysteine) peptidase inhibitor, 
clade A, member 3N 
Vwf Von Willebrand factor homolog 
 
Specific genes enriched by the single (1x) LPS challenge of mice. FC ≥ 2, FDR < 0.05
Symbol Gene 
Gh  growth hormone  
Gpx3  glutathione peroxidase 3  
Ngp  neutrophilic granule protein  
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